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ABSTRACT 68 
Antimicrobial peptides (AMPs) and their synthetic mimics have received recent interest as new alternatives to traditional 69 
antibiotics in attempts to overcome the rise of antibiotic resistance in many microbes. AMPs are part of the natural defenses of 70 
most living organisms and also they have a unique mechanism of action against bacteria. Herein, a new series of short amphiphilic 71 
cationic peptidomimetics were synthesized by incorporating the 3'-amino-[1,1'-biphenyl]-3-carboxylic acid backbone to mimic the 72 
essential properties of natural AMPs. By altering hydrophobicity and charge, we identified the most potent analogue 25g that was 73 
active against both Gram-positive Staphylococcus aureus (MIC = 15.6 µM) and Gram-negative Escherichia coli (MIC = 7.8 µM) 74 
bacteria. Cytoplasmic permeability assay results revealed that 25g acts primarily by depolarization of lipids in cytoplasmic 75 
membranes. The active compounds were also investigated for their cytotoxicity to human cells, lysis of lipid bilayers using 76 
tethered bilayer lipid membranes (tBLMs) and their activity against pre-established biofilms of S. aureus and E. coli. 77 
 78 
Keywords: antimicrobial peptide, peptidomimetics, membrane disruption, antibiofilm activity. 79 
 80 
1. Introduction 81 
Antibiotic resistance in bacteria is a major concern facing global public health. Multidrug resistant strains of Gram-positive 82 
bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE), 83 
and vancomycin-resistant Enterococci faecalis (VRE), and Gram-negative bacteria such as Escherichia coli, Klebsiella 84 
pneumoniae, and Pseudomonas aeruginosa, have emerged as major causes of hospital and community-acquired infections [1]. 85 
Particularly, Gram-positive bacteria such as MRSA account for a high percentage of hospital-acquired infections [1, 2]. Due to the 86 
increasing resistance of bacterial strains against conventional antibiotics, efforts have been made to investigate naturally-occurring 87 
antimicrobial peptides (AMPs) and their derivatives as alternative antimicrobial agents [3-5]. AMPs such as PMX30063 and 88 
LTX109 are currently in clinical trials [6-8]. Although some promising AMPs are in the pipeline, there is still an urgent need for 89 
the development of new antibiotic scaffolds. 90 
 91 
AMPs are widespread in nature and serve as the first-line of defense against microbial attack in insects, plants, amphibians, and 92 
mammals [9-12]. Unlike conventional antibiotics, AMPs act via non-receptor interactions, which make it difficult for bacteria to 93 
develop resistance to AMPs. Most cationic antimicrobial peptides possess a rigid secondary structure and adopt an amphipathic 94 
conformation such that their positively-charged face interacts electrostatically with the negatively-charged membrane surface, 95 
while their hydrophobic face inserts into the lipophilic interior of the membrane [13, 14]. The broad-spectrum antimicrobial 96 
peptide pexiganan, which acts via disruption of bacterial cell membranes, has reached phase III clinical trials [15]. Only a few 97 
naturally-occurring AMPs have been used clinically, including polymyxin B and colistin (polymyxin E), due to their in vivo 98 
toxicity, susceptibility to proteolytic degradation, poor activity in the presence of salts and cytotoxicity to the host cells [16]. 99 
Produced through solid-phase synthesis, AMPs also have high manufacturing costs [17]. 100 
 101 
The drawbacks of conventional AMPs have stimulated the development of peptidomimetics [18], which are synthetic nonpeptidic 102 
molecules designed to mimic the properties of peptides. The various kinds of peptidomimetics include α-peptides [19], β-peptides 103 
[20], peptoids [21-23], β-turn mimetics [24], cationic β3R3-peptides [25] and lipopeptides [26]. In particular, a number of 104 
structurally simple, cationic peptidomimetics possessing natural or unnatural amino acids and with amphipathic character have 105 
been investigated as antibacterial agents [27, 28]. Svendsen and co-workers have synthesized a range of peptides of variable 106 
length utilizing arginine and tryptophan aminoacids, and showed good minimal inhibitory concentration (MIC) of  2.5 μg mL−1 107 
against Staphylococcus aureus and 5 μg mL−1 against Escherichia coli [29]. An ultra-short pyrazole-based peptidomimetics 108 
showed a MIC of 4 μg mL−1 against MRSA and was four times more potent than melittin [30]. Pyne and co-workers have 109 
developed C2-symmetric binaphthyl-containing peptidomimetics that showed excellent antimicrobial activity against both Gram-110 
positive and Gram-negative bacterial pathogens [31]. Haldar and co-workers designed aryl-alkyl-lysine-based peptide mimics that 111 
mimicked the membrane-active properties of natural AMPs [32]. Their group also investigated cationic small molecules with 112 
spatial control of hydrophobicity to minimize toxicity against human erythrocytes while still maintaining antibacterial activity 113 
[33].  114 
 115 
Our research group has recently synthesized short glyoxamide-based peptidomimetics via the ring-opening reaction of N-116 
naphthoylisatins with amines and amino acids [34, 35]. As part of an ongoing program to develop short antimicrobial 117 
peptidomimetics, we were interested in utilizing the biphenyl backbone due to its frequent presence in medicinal chemistry [36, 118 
37]. In an analysis of scaffolds of pharmacologically active molecules, biphenyl was found to be present in 2.1% of reference drug 119 






40], such as the antibacterial compounds MC21-A (1) and MC21-B (2) isolated from marine bacterium Pseudoalteromonas 121 
phenolica [41, 42]. The biphenyl-containing antibacterial compounds biphenomycin A (3) and B (4) were isolated from the 122 
cultured broth of Streptomyces griseorubiginosus 43608 [43-45]. Antibiotics such as arylomycin A2 (5), arylomycin B2 (6) and 123 
vancomycin also contain biphenyl moieties.  124 
 125 
Fig. 1 Biphenyl-containing antibacterial compounds, with the biphenyl motif highlighted in blue. 126 
 127 
In this work, we designed a unique scaffold for developing short antimicrobial peptidomimetics by utilizing a 3, 3’-substituted 128 
biphenyl unit as the key hydrophobic backbone to mimic the structural and biological properties of many AMPs. The segregation 129 
of hydrophobic (R1) and cationic (R2) groups via the biphenyl core confers amphipathic character to the entire molecule (Fig. 2). 130 
Importantly, the modular design of this scaffold allows for ready optimization of the biphenyl-based peptidomimetics simply by 131 
varying the nature of the hydrophobic (R1) and cationic (R2) groups. 132 
 133 
Fig. 2 General structure of biphenyl based peptidomimetics 134 
 135 
The biphenyl-based peptidomimetics synthesized in this work were classified into two series based on the length of the 136 
hydrophobic group (R1) attached to the molecule. Series I (23a-23e) incorporated a single tryptophan (Trp) group at the 3-position 137 
of biphenyl, whereas series II (25a-25g) incorporated a tryptophan-phenylalanine (Trp-Phe) dipeptide at the same position. The 138 
selection of Trp was based on its ability to interact with the interfacial region of the bacterial membranes, thereby anchoring the 139 
biphenyl derivatives to lipid bilayers [46]. The cationic groups (R2) were incorporated at the 3’-position of biphenyl, and they 140 
included 1,2-diaminoethane, 1-(2-aminoethyl)guanidine, and amino acids such as arginine and lysine. This demonstrated the 141 
importance of short non-natural amine and guanidine groups over cationic amino acids. Arginine and 1-(2-aminoethyl)guanidine 142 
were chosen because the guanidine group exhibits a stronger electrostatic interaction and more extensive hydrogen bonding with 143 
the negatively-charged phospholipids of the bacterial cell membrane [47]. 144 
 145 
The synthesized compounds were evaluated for biological activity against Gram-positive and Gram-negative bacterial strains. In 146 
addition, cytotoxicity was also investigated for selected potent antimicrobial compounds. To study how the active compounds 147 
interacted with lipid membranes, tethered bilayer lipid membranes (tBLMs) in association with electrical impedance spectroscopy 148 
was employed. In addition, the ability of the compounds to alter cytoplasmic permeability was assessed by using the membrane 149 
potential-sensitive cyanine dye diSC3-5. Finally, the ability of the compounds to inhibit the biofilm formation of S. aureus and E. 150 
coli was also evaluated. 151 
 152 
2. Results and discussion 153 
 154 
2.1 Design and synthesis of biphenyl derived peptidomimetics 155 
   156 
The acid 17 was synthesized by deprotecting the Boc group of 12 with TFA, followed by amide formation with 15 and subsequent 157 
ester hydrolysis using aqueous sodium hydroxide. On coupling 17 with different amines (18a-18g) respective amides 24a-24g 158 
were yielded and the deprotection of 24a-24g gave the series II compounds (25a-25g). The synthesis of amines 18b, and 18d-18g 159 
were shown in scheme2. The guanylation reaction using N,N′-Di-Boc-1H-pyrazole-1-carboxamidine provides the corresponding 160 
amine 18b. The amino ester 18d was prepared from NH2-Arg(Mtr)-OH using thionyl chloride and methanol. The acids 21(X’), 161 
21(X’), 20(Y’) were used to synthesize the amides 21a, 20b, 21b using PyBOP/CH2Cl2 coupling agent, and subsequent Fmoc 162 







Scheme 1. Synthesis of compounds 13 and 17. Reagents and conditions: a) 8 (1.1 equiv), Pd(PPh3)4 (0.03 equiv), aq. 2M Na2CO3 (3.0 equiv), 1,4-dioxane, reflux, 165 
overnight, 65%; b) 10% Pd/C, H2 balloon, THF, rt, overnight, 90%; c) EDCI (1.2 equiv), HOBt (1.0 equiv), DIEA (2.5 equiv), DMF, rt, 8 h, 63%; d) aq. 1N 166 
NaOH(2.0 equiv), THF, MeOH, rt, overnight, 90% e) TFA, CH2Cl2, RT, 4h, 89%; f) EDCI (1.2 equiv), HOBt (1.0 equiv), DIEA (2.5 equiv), DMF, rt, 8h, 54%; g) 167 
aq. 1N NaOH (2.0 equiv), THF, MeOH, rt, overnight, 89%; h) EDCI (1.2 equiv), HOBt (1.0 equiv), DIEA (2.5 equiv), DMF, rt, 8 h-overnight, 52-84%; i) TFA, 168 





Scheme 2. Synthesis of 18b, 18d-18g. Reagents and conditions: a) N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (0.1 equiv), THF, rt, 30 min, crude; b) SOCl2 (1.5 174 







The biphenyl derivative 29 attached with guanidine without any hydrophobic group was synthesized as shown in scheme3.  177 
The biphenyl ester 9 was hydrolyzed to acid 26 and coupling with 18b to afford the amide 27 and, subsequent deprotection with 178 
TFA gave 29. Finally, 35 without the biphenyl backbone but intact with hydrophobic and cationic group was synthesized from L-179 
Tryptophan 30. The acid 33 was obtained by the sequential formation of dipeptide 32 from 30, followed by ester hydrolysis. The 180 
amide 34 was obtained on coupling 33 with 18b, and it was deprotected with TFA to yield 35 (Scheme 4). 181 
 182 
  183 
Scheme 3. Synthesis of compound 29. Reagents and conditions: a) aq. 1N NaOH (2.0 equiv), THF, MeOH, rt, overnight, 90%; b) EDCI (1.2 equiv), HOBt (1.0 184 
equiv), DIEA (2.5 equiv), DMF, rt, overnight, 80%; c) TFA, CH2Cl2, rt, 4h-overnight, 90%; d) N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (1.0 equiv), Et3N (2.0 185 
equiv), THF, RT, 6 h, 85% e) 10% Pd/C, H2 balloon, rt, 5 h, 40%. 186 
 187 
 188 
 Scheme 4. Synthesis of compound 35. Reagents and conditions: a) SOCl2 (1.5 equiv), MeOH, RT, overnight, 90%; b) EDCI (1.2 equiv), HOBt (1.0 equiv), DIEA 189 
(2.5 equiv), DMF, rt, overnight, 65%; c) 1N NaOH(aq) (2.0 equiv), THF, MeOH, rt, overnight, 91%; d) EDCI (1.2 equiv), HOBt (1.0 equiv), DIEA (2.5 equiv), 190 
DMF, rt, overnight, 45%; e) TFA, CH2Cl2, RT, overnight, 47%. 191 
 192 
2.2 Antimicrobial activity study 193 
 194 
The antimicrobial activities of the newly synthesized peptidomimetics were assessed against the Gram-positive bacterium 195 
Staphylococcus aureus [SA38], and two Gram-negative bacteria, Pseudomonas aeruginosa [PA01], and Escherichia coli [K12] 196 
are summarized in table1. 197 
 198 
The series I compounds 23a-23e were tested against Gram-positive bacterium Staphylococcus aureus [SA38]. The compound 23b 199 
(MIC = 62.5 µM) in which the biphenyl group segregated with tryptophan hydrophobic group and simple guanidine cationic 200 
group showed more activity compared to simple amine cationic group 23a (MIC = 125 µM). The compound 23b containing 201 
simple guanidium cationic moiety which mimic the ariginine amino acid found in natural AMPs displayed the good activity. The 202 
MIC values of 23c (31.2 µM) and 23d (62.5 µM) attached with the Lys-ester and Arg-ester cationic groups are compared with 203 
23a and 23b by maintaining the total net charge and hydrophobicity of the compounds. We noticed that the amine containing 204 
cationic group of lysine methyl ester 23d showed four-fold increase in antibacterial activity compared to the 23a. Interestingly, the 205 
similar antibacterial activity of 23b and 23d revealed that the simple guanidine cationic group is enough to mimic the arginine. 206 
The antibacterial activity of compound 23e (MIC = 31.2 µM), and 23c remains same even though the net cationic charge is 207 
increased. This could be due to the imbalance of the peptide hydrophobicity and charge distribution. Although, the series I 208 
compounds 23a-23e found to be active against S. aureus, these compounds did not have significant activity against the two Gram-209 
negative bacteria, Pseudomonas aeruginosa [PA01], and Escherichia coli [K12]. Based on the results from series I, increase in the 210 
net cationic charge did not show any profound antibacterial effect against Gram-positive and Gram-negative bacterial strains.  211 
 212 
The series II compounds 25a-25g were made on hypothesis that the increase in hydrophobicity will enhance the antibacterial 213 
activity and to understand the effect of hydrophobicity along with the cationic character against the Gram-negative pathogens. All 214 
the compounds 25a-25g were tested against the Gram-positive bacterium Staphylococcus aureus [SA38]. As expected 25a (MIC 215 
= 62.5 µM) and 25b (MIC = 15.6 µM) containing excess hydrophobic phenylalanine group showed excellent activity compared to 216 
less hydrophobic compounds 23a (MIC = 125 µM) and 23b (MIC = 62.5 µM). The increase in hydrophobicity of 23c (31.2 µM) 217 
did not improve the MIC of 25c. Whereas, in compound 25d (31.2 µM) the activity increased two-fold compared to 23d (62.5 218 
µM). This may be resulted due to the increase in hydrophobic bulkiness along with the extensive hydrogen bonding of guanidine 219 
group. 25e (MIC = 31.2 µM) retained the same activity compared to 23e (MIC = 31.2 µM) though the hydrophobicity is increased 220 
may be due to the net positive charge equals with the number of hydrophobic group. We hypothesized that if the net positive 221 






25f (31.2 µM) showed same activity after replacing with one guanidine of 25e. As anticipated the compound 25g (MIC = 15.6 223 
µM) replaced with the two-guanidine by attaching arginine in place of lysine group in 25f showed excellent activity compared to 224 
25e (MIC = 31.2 µM) probably due to the strong hydrogen bonding with the negatively charged phospholipids of bacterial cell 225 
membrane.  226 
 227 
25a-25g were also tested against Gram-negative bacteria Escherichia coli [K12]. Compounds 25a, 25c, 25d did not show notable 228 
antibacterial activity. The compound 25b (MIC = 31.2 µM), with the increased hydrophobicity compared to 23e (MIC = >125 229 
µM) showed dramatically four-fold improvement against E. coli. The antibacterial activity of cationic peptides on Gram-negative 230 
bacteria is influenced by two steps to overcome the outer-membrane barrier. The high membrane bound concentration of the 231 
cationic peptides facilitates the outer-membrane permeabilization and in the final step the inner membrane damage causes the cell 232 
lysis [48]. In this step, the hydrophobic interactions become dominant. This clearly suggests the importance of activity of 25b 233 
compared to 23e. The compounds 25f (MIC = 15.6 µM), and 25g (MIC = 7.8 µM) containing guanidine cationic groups displayed 234 
good activity against E. coli compared to 25c (MIC = 125 µM) and 25e (MIC = 31.2 µM) containing the amine cationic groups. 235 
These results evidently showed that the electrostatic attraction played the decisive role for the excellent activity against the E. coli. 236 
The compound 29 (62.5 µM) retains the biphenyl backbone showed the similar activity of 23b against S. aureus and E. coli even 237 
though the hydrophobic tryptophan group was removed. This could be due to the hydrophobicity of the biphenyl backbone. 238 
 239 
Finally, the MIC results of 35 without the biphenyl backbone (>250 µM) compared with 23b (62.5 µM) against Staphylococcus 240 
aureus [SA38]. The antibacterial activity is totally lost after the removal of biphenyl backbone from the active compound 23b. 241 
The MIC results confirms the biphenyl backbone plays a major role in balancing the hydrophobicity and amphipathicity which are 242 
considered as the key parameters for the antibacterial activity against Gram-positive and Gram-negative bacterial strains.  243 
 244 
Overall, the structure activity relationship (SAR) draw the inference regarding the antibacterial activity of the biphenyl backbone 245 
peptidomimetic derivatives against S. aureus and E. coli. Firstly, the series II compounds with excess hydrophobic group showed 246 
good to excellent antimicrobial activity against S. aureus and E. coli. Secondly, the amphipathic nature played a crucial role in 247 
determining the antimicrobial activity. The antibacterial activity of compounds 25c-25f remain intact against S. aureus even after 248 
increasing the net positive charge. Among all the synthesized biphenyl derivatives, 25b and 25g displayed the most potent 249 
antibacterial activity against S. aureus (15.6 µM). Finally, 25g revealed that an increase in cationic charge by utilizing guanidine 250 
groups along with increase in hydrophobicity produced excellent activity against Gram-negative E. coli (7.6 µM) compared to the 251 
corresponding amine compound.  252 
 253 
The active peptidomimetic compound 25g which contains less number of amino-acids is comparable with the MIC of MSI-78. 254 
MSI-78 (also known as pexiganan) is a chimera of magainin and melittin peptides [49]. This peptide was chosen as a reference 255 
compound as it is currently in Phase-III clinical trials and one of the most well-studied amphipathic antimicrobial peptides. 256 
Resistant strains of bacteria cannot be generated against MSI-78 even after repeated exposure to sub-inhibitory concentrations 257 
[15], and many studies have shown that the antimicrobial action of the peptide involves disruption of bacterial membranes [50, 258 
51].  259 
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 262 
2.3 Toxicity against human cells 263 
 264 
To further evaluate the utility of these biphenyl derivatives as antimicrobial agents, their specificity for bacterial cells over human 265 
cells was determined. Therefore, the in vitro toxicity of the most active compounds (23b, 23d, 25b-25g) was assessed against 266 
MRC-5 normal human lung fibroblasts using the Alamar Blue (Resazurin) assay [54]. A dose-response curve was generated for 267 
each compound (shown in supplementary material Fig. S2) at concentrations ranging from 1-350 μM and their IC50 values were 268 
determined (shown in supplementary material Fig. S3). All of the tested compounds displayed very low toxicity (IC50 >300 µM) 269 
towards human cells. Although amphipathic antibacterial agents are often cytotoxic, our compounds did not show noticeable 270 
cytotoxicity upto the concentration of 350 µM.  271 
 272 
2.4 Lipid bilayer membrane interactions 273 
 274 
The compounds ability to interact with lipid bilayers was assessed using tethered bilayer lipid membranes (tBLMs) in association 275 
with AC electrical impedance spectroscopy.[55, 56]. Compounds which are shown membrane conduction at concentration of 10 276 
µM are only discussed. Membrane conduction responses of a zwitterionic phospholipid membrane to compounds 25b-25e 277 
increased with increasing concentration of compounds (Fig. 3A). Significant conduction changes are evident at concentrations 278 
equal to or higher than 10 µM. Interestingly, these responses are more muted in negatively-charged phospholipid membranes 279 
which mimic the negatively charged bacterial cell membranes (Fig. 3B). 280 
 281 
The changes in membrane conduction are modest when compared to that produced by α-hemolysin or gramicidin-A [56, 57] 282 






spanning ion channel-like pores. Alternatively, the changes in membrane conduction could be the result of the formation of 284 
toroidal pore-like structures in the membrane. Either the compounds form a part of the lipidic toroidal pore themselves, or they 285 
independently induce phospholipidic toroidal pore formation by altering the critical packing parameter of the membrane[58].  286 
 287 
The membrane capacitance changes increased with compound concentration in both zwitterionic (Fig. 3C) and negatively-charged 288 
(Fig. 3D) tBLMs, with the exception of compound 25d which exhibited a slight decrease in capacitance at high concentrations in 289 
negatively-charged membranes. An increase in capacitance is indicative of a thinning of the lipid membrane and/or an increase in 290 
membrane dielectric caused by the presence of water molecules. This indicates these compounds may follow mechanism of pore 291 
formation like AMPs by membrane thinning effect [59]. 292 









































































































Fig. 3. Change in conduction in (A) zwitterionic and (B) negatively-charged tBLMs in response to increasing concentrations of compounds 25b-25e.. Change in 293 
membrane capacitance in (C) zwitterionic and (D) negatively-charged tBLMs in response to increasing concentrations of compounds 25b-25e. 294 
 295 
Notably, the change in membrane conduction at 10 µM was correlated with antimicrobial activity, with compounds having lower 296 
MIC values (compounds 25c-25e) showing greater positive changes in membrane conduction in zwitterionic lipids than 297 
compounds with higher MIC values 25b (Fig. 4A). In negatively-charged lipids, however, the results were mixed and there was 298 
no clear relationship between MIC and conductance change (Fig. 4B). This would suggest that the effectiveness of these 299 
compounds is not so much related to their overall net cationic charge, rather their ability to insert into the bilayer proper. To test 300 
the hypothesis that the tryptophan moiety plays a significant role in membrane disruption, the change of conductance induced by 301 
compound 29, which lacks any Trp residue, was tested. As expected, compound 29 exhibited no change in membrane conduction 302 
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Fig. 4. The change in tBLM conduction of the various antimicrobial compounds at 10 µM in (A) zwitterionic and (B) negatively-charged membranes.  305 
 306 
2.5 Cytoplasmic membrane depolarization 307 
 308 
We evaluated the disruption effect of the biphenyl derivatives on the bacterial cytoplasmic membrane using the membrane 309 
potential-sensitive dye diSC3-5 (3,3'-dipropylthiadicarbocyanine iodide). The distribution of diSC3-5 between the cell membrane 310 
and periphery medium is dependent on the cytoplasmic membrane potential gradient. The dye readily partitions into the bacterial 311 
cell membrane and aggregates within the membrane, causing self-quenching. If the antimicrobial compounds perturb the cell 312 








the fluorescence intensity of the dye increases. As shown in Fig. 5, compounds 23b, 23d, 25b, 25e, 25f, and 25g (added at 0.5×, 314 
1×, 2× or 4× MIC) induced disruption of the cytoplasmic membrane of S. aureus in a time and concentration-dependent manner. 315 
Interestingly, the most active compound 25g showed an increase in fluorescence intensity even at sub-MIC levels within 3 min. 316 
Similarly, increases in fluorescence intensity of 25e and 25f also occurred at 1× MIC within 3 minutes. 317 
  318 
We also conducted the cytoplasmic permeability assay on Gram-negative bacterium E. coli (K12) with the most active compound 319 
25g. 25g also perturbs the cell membrane led to similar disruption of diSC3-5 fluorescence intensity (Fig. 5G), indicating that the 320 
cell membrane of both Gram-positive and Gram-negative bacteria can be disrupted. Taken together, these observations indicate 321 
that the biphenyl amphiphilic compounds can readily permeabilize the bacterial membrane, thus resulting in bacterial death. 322 
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 326 
Fig. 5. (A-F) S. aureus cytoplasmic membrane disruption promoted by 23b, 23d, 25b, 25e, 25f, 25g. (G) E. coli cytoplasmic membrane disruption promoted by 327 
25g. Error bars represent the standard error of triplicates (n = 3).  328 
 329 
2.6 Antibiofilm activity 330 
 331 
The ability of the amphiphilic biphenyl derivatives to inhibit established S. aureus or E. coli biofilms was measured at 250 µM 332 
(Fig. 6). In general, the compounds showed low level of inhibition of biofilm formation. Compound 23b showed the highest level 333 
of disruption against S. aureus and E. coli of 41% and 39% respectively at 250 µM. Meanwhile, compound 25e displayed 30% 334 
inhibition against S. aureus biofilms but only 8% activity against biofilms of E. coli. The pre-established biofilms are harder to 335 
eradicate and have limited data available on novel AMPs with anti-biofilm properties [60]. Compound 23b containing less 336 
hydrophobic and cationic groups moderately disrupted both the S. aureus or E. coli biofilms compared to active antibacterial 337 
compounds. These results revealed that the increase in cationic charge and hydrophobicity elevates the activity against planktonic 338 
cells, but they are unable to disrupt the large aggregates of bacteria surrounded by an extracellular matrix. Previous studies have 339 
used a similar method for measuring the antibiofilm properties of cationic peptides, that is allowing the biofilm to form in the 340 
presence of the peptide [61]. Cirioni et al.[61] found that at a concentration of half the MIC, MSI-78 (pexiganan) was able to 341 











which showed 39% inhibition of biofilm production by another Gram-negative bacterium E. coli but at a concentration of 31 times 343 
the MIC. In an alternative biofilm study, where biofilms were formed prior to the addition of MSI-78 (pexiganan) was unable to 344 
minimize the amount of biofilm produced by with P. aeruginosa, E. coli or S. aureus even at a concentration of 128 times its 345 
MIC. However, in a similar preformed biofilm assay, another naturally occurring peptide, LL-37 which is also a membrane 346 
disrupting peptide [62], reduced the biofilm mass by approximately 40% at 4 times its MIC [63]. Thus, the current compounds 347 
show similar antibiofilm capabilities to cationic antimicrobial peptides, but future studies should examine whether the current 348 

















































Fig. 6. Percentage of remaining biofilm of S. aureus and E. coli after 24 h treatment with the synthesized compounds at 250 µM. The control represents the pre-351 
established biofilms without any compounds. Error bars represent the standard error of triplicates (n = 3).  352 
 353 
3. Conclusion 354 
 355 
In conclusion, we have developed novel peptidomimetics based on the 3,3’-biphenyl structural scaffold. The systematic tuning of 356 
hydrophobicity and cationic charge of the peptidomimetics resulted in moderate to excellent antibacterial activities. 25g, the 357 
amphipathic peptidomimetic compound in which the hydrophobic Trp-Phe and cationic Arg-aminoethylguanindine segregated by 358 
biphenyl backbone showed excellent antibacterial activity against S. aureus (15.6 µM) and E. coli (7.8 µM) without cytotoxicity 359 
against mammalian cells. Based on the results of cytoplasmic permeability assay and tBLMs-AC impedance spectroscopy, we 360 
propose that the biphenyl peptidomimetics exhibit bacterial cell membrane disruption mechanism similar to most AMPs. The 361 
importance of tryptophan in mechanism of action was also revealed by compound 29. In addition, 23b biphenyl attached with 362 
hydrophobic Trp and cationic aminoethyl guanidine could disrupt biofilms of S. aureus and E. coli at 250 µM. Collectively, our 363 
results suggest biphenyl is a versatile core about which hydrophobic and cationic amino acids can be arranged in order to generate 364 
short cationic amphipathic peptidomimetics that mimic natural AMPs. 365 
 366 
4. Experimental section 367 
 368 
4.1 General notes 369 
 370 
All chemical reagents were purchased from commercial sources (Combi-Blocks, Chem-Impex and Sigma Aldrich) and used 371 
without further purification. Solvents were commercial and used as obtained. Reactions were performed using oven-dried 372 
glassware under an atmosphere of nitrogen and in anhydrous conditions (as required). Room temperature refers to the ambient 373 
temperature. Yields refer to chromatographically and spectroscopically pure compounds unless otherwise stated. Reactions were 374 
monitored by thin layer chromatography (TLC) plates pre-coated with Merck silica gel 60 F254. Visualization was accomplished 375 
with UV light, a ninhydrin staining solution in n-butanol. Flash chromatography and silica pipette plugs were performed under 376 
positive air pressure using Silica Gel 60 of 230–400 mesh (40–63 μm) and also using Grace Davison LC60A 6- μm for reverse 377 
phase chromatography. Infrared spectra were recorded using a Cary 630 ATR spectrophotometer. Melting points were obtained 378 
using a OptiMelt melting point apparatus and are uncorrected. High-resolution mass spectrometry was performed by the 379 
Bioanalytical Mass Spectrometry facility, UNSW. Proton and Carbon NMR spectra were recorded in the solvents specified using 380 
a Bruker DPX 300 or a Bruker Avance 400 or 600 MHz spectrometer as designated. Chemical shifts (δ) are quoted in parts per 381 
million (ppm), to the nearest 0.01 ppm and internally referenced relative to the solvent nuclei. 1HNMR spectral data are reported 382 
as follows [chemical shift in ppm; multiplicity in br, broad; s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; sext, sextet; 383 
sept, septet; m, multiplet; or as a combination of these (e.g. dd, dt etc.)]; coupling constant (J) in hertz, integration, proton count 384 
and assignment. 385 
 386 
4.2 General methods 387 
 388 
4.2.1 Procedure 1: peptide formation method a 389 
 390 
To a stirred solution of an acid (1 equiv), amine (1.0 equiv), HOBt (1.0 equiv), DIEA (2.5 equiv) in DMF (3 – 5 mL) EDCI (1.2 391 
equiv) was added portion-wise. The reaction was stirred overnight before the solvent was removed under reduced pressure and the 392 
resultant residue subjected to flash chromatography (2-5% MeOH/CH2Cl2 as the eluent) to afford the desired compound. 393 
 394 








To a stirred solution of an acid (1 equiv), amine (1.0 equiv), HOBt (1.0 equiv), PyBOP (1.1 equiv) in CH2Cl2 (3 – 5 mL) DIEA 397 
(2.0 equiv) was added dropwise. The reaction was stirred overnight before the solvent was removed under reduced pressure and 398 
the resultant residue subjected to flash chromatography (2-5% MeOH/CH2Cl2 as the eluent) to afford the desired compound. 399 
 400 
4.2.2 Procedure 3: N-fmoc deprotection 401 
 402 
To a stirred solution of the Fmoc-protected peptide in DMF (3.0 – 5.0 mL)was added piperidine (2.0 equiv). The resultant solution 403 
was then stirred at rt for overnight. The solvent was then removed under reduced pressure and purified using flash 404 
chromatography ( 5% of 100:10:1; CHCl3:MeOH: aqueous NH3 and 95% of CH2Cl2) as eluent The resultant compounds isolated 405 
as TFA salt. 406 
 407 
4.2.3 Procedure 4: N-boc and Pbf deprotection 408 
 409 
To a stirred solution of the boc/Pbf protected peptide in CH2Cl2 (3.0 mL) was added TFA (3.0 mL). The reaction mixture was 410 
stirred at room temperature overnight before the solvent was removed under reduced pressure. After triturating with diethyl ether, 411 
the residue was concentrated to dryness. For Pbf and deboc of guanidine the residue was dissolved in CH2Cl2 and CH3CN and 412 
precipitated by addition of diethyl ether and filtered and dried. Some of the compounds were purified using reverse phase 413 
chromatography with 40% CH3CN/ H2O as eluent utilizing GRACE instrument.  414 
 415 
4.3 Preparation of derivatives 416 
 417 
4.3.1. 1H NMR and 13C NMR spectra of Methyl 3'-nitro-[1,1'-biphenyl]-3-carboxylate (9) 418 
 419 
1-Bromo-3-nitrobenzene 7 (5.0 g, 24.7 mmol), (3-(Methoxycarbonyl)phenyl)boronic acid  8 (5.34 g, 29.7 mmol), 420 
tetrakistriphenylphosphinepalladium(0) (1.40 g, 1.23 mmol), sodium carbonate (2 M) (37 mL, 74.1 mmol), and 1,4-dioxane (120 421 
mL) were combined and the reaction mixture was heated at reflux under a nitrogen atmosphere for 16 h.The reaction mixture was 422 
allowed to cool at room temperature and partitioned between ethyl acetate and water.  The organic phase was separated, dried over 423 
magnesium sulfate, filtered, and the filtrate was concentrated to give a liquid. The crude product was purified by flash 424 
chromatography over silica with a hexanes:ethyl acetate gradient (100:0 to 90:10) to give (4.12 g, 65%) the title compound 9 as a 425 
yellow solid; m.p.: 96.5–96.6 °C;  1H NMR (400 MHz, DMSO-d6): δ 8.45 (t, J = 4.00 Hz, 1H), 8.27-8.24 (m, 2H), 8.19 (dd, J = 426 
4.00, 8.00 Hz, 1H), 8.08-8.01 (m, 2H), 7.79 (t, J = 8.00 Hz, 1H), 7.68 (t, J = 8.00 Hz, 1H), 3.90 (s, 3H),; 13C NMR (100 MHz, 427 
DMSO-d6): δ 166.4, 148.9, 141.0, 138.8, 133.9, 132.3, 131.1, 131.0, 130.2, 129.6, 127.9, 123.1, 121.8, 52.8; IR (ATR): νmax 428 
3312, 2953, 2342, 1722, 1520, 1429, 1348, 1301, 1236, 1191, 1104, 963, 883, 839, 801, 690; HRMS (ESI): m/z calcd for 429 
C14H11NO4 Na [M + Na]+: 280.0586; found: 280.0579. 430 
 431 
4.3.2 1H NMR and 13C NMR spectra of Methyl 3'-amino-[1,1'-biphenyl]-3-carboxylate (10) 432 
 433 
To a stirred solution of 3'-nitro-[1,1'-biphenyl]-3-carboxylic acid methyl ester 9 (4.0 g, 15.5 mmol) in anhydrous THF (100 mL) 434 
under nitrogen atmosphere 10% palladium on activated charcoal (1.0 g) was added. The reaction was evacuated and placed under 435 
a hydrogen atmosphere and stirred overnight. The reaction mixture was filtered through Celite, and the solvent was removed 436 
under reduced pressure to yield gray oil. The residue was chromatographed on silica, eluting with 3:1 hexane/EtOAc. 437 
Concentration of the appropriate fractions provided the product as an off-white solid (3.17 g, 90% yield); m.p.: 84.9–85.1 °C; 1H 438 
NMR (400 MHz, CDCl3): δ 8.28 (t, J = 4.00 Hz, 1H), 8.03 (dt, J = 2.00, 5.00 Hz, 1H), 7.79-7.76 (m, 1H), 7.51 (t, J = 12.00 Hz, 439 
1H), 7.27 (q, J = 4.00 Hz, 1H), 7.06-7.03 (m, 1H), 6.97 (t, J = 4.00 Hz, 1H), 6.75-6.73 (m, 1H), 3.96 (s, 5H),; 13C NMR (100 440 
MHz, CDCl3): δ 167.1 146.6, 141.6, 141.3, 131.5, 130.6, 129.9, 128.7, 128.3, 128.2, 117.7, 114.6, 113.9, 52.2; HRMS (ESI): m/z 441 
calcd for C14H13NO2 Na [M + Na]+ 250.0844; found: 250.0838. 442 
 443 
4.3.3. 1H NMR and 13C NMR spectra of Methyl (S)-3'-(2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanamido)-[1,1'-444 
biphenyl]-3-carboxylate (12) 445 
 446 
The title compound was prepared via protocol 1, using 10 (1.0 g, 4.4 mmol) and (tert-butoxycarbonyl)-L-tryptophan (1.33 g, 4.4 447 
mmol) to afford the coupled product 12 as an off-white solid (1.42 g, 63%);  m.p.: 107.3–108.0 °C; 1H NMR (400 MHz, DMSO-448 
d6): δ 10.82 (s, 1H), 10.17 (s, 1H), 8.17 (s, 1H), 7.98-7.91 (m, 3H), 7.69-7.62 (m, 3H), 7.45-7.38 (m, 2H), 7.32 (d, J = 8.00 Hz, 449 
1H), 7.19 (s, 1H), 7.05 (t, J = 8.00 Hz, 1H), 6.99-6.97 (m, 2H), 4.41-4.39 (m, 1H), 3.90 (s, 3H), 3.18-2.99 (m, 2H), 1.34 (s, 9H),; 450 
13C NMR (100 MHz, DMSO- d6): δ 171.8, 166.5, 155.8, 140.9, 140.2, 139.9, 136.5, 131.9, 130.8, 130.8, 128.7, 127.7, 127.4, 451 
124.2, 122.1, 121.3, 119.4, 118.6, 118.1, 111.8, 118.1, 111.8, 110.4, 78.6, 56.4, 52.8, 28.6, 28.3; IR (ATR).νmax 3304, 2330, 452 
2099, 1665, 1605, 1528, 1491, 1423, 1303, 1250, 1160, 1111, 1082, 1010, 856, 733, 690; HRMS (ESI): m/z calcd for C30H31N3O5 453 
Na [M + Na]+ 536.2161; found: 536.2153. 454 
 455 
4.3.4. 1H NMR and 13C NMR spectra of (S)-3'-(2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanamido)-[1,1'-biphenyl]-3-456 
carboxylic acid (13) 457 
 458 
To a solution of 12 (1.2 g, 1.81mmol) in THF (10.0 mL) and MeOH (10.0 mL), was added a 1N NaOH(aq) (3.63 mL, 3.63mmol) 459 







acidified with 1N HCl and then extracted with CH2Cl2 (2 X 100 mL) and then the solvent was removed under reduced pressure to 461 
yield 13 (1.00 g, 85%) as an off-whit solid; m.p.: 140–140.3 °C; 1H NMR (400 MHz, DMSO-d6): δ 13.10 (s, 1H), 10.82 (s, 1H), 462 
10.17 (s, 1H), 8.18 (t, J = 4.00 Hz, 1H), 7.97-7.95 (m, 2H), 7.90-7.87 (m, 1H), 7.69-7.66 (m, 2H), 7.61 (t, J = 8.00 Hz, 1H), 7.45-463 
7.38 (m, 2H), 7.32 (d, J = 8.00 Hz, 1H), 7.19 (s, 1H), 7.06 (t, J = 4.00 Hz, 1H), 6.98 (t, J = 8.00 Hz, 2H), 4.41 (q, J = 8.00 Hz, 464 
1H), 3.19-3.14 (m, 1H), 3.05-3.00 (m, 1H), 1.34 (s, 9H); 13C NMR (100 MHz, DMSO- d6): δ 171.7, 167.6, 155.8, 140.7, 140.2, 465 
140.1, 136.5, 132.0, 129.9, 128.8, 127.8, 127.6, 124.3, 122.1, 121.4, 119.3, 119.1, 118.7, 118.1, 111.8, 110.4, 79.6, 78.6, 56.3, 466 
28.6, 28.3; IR (ATR).νmax 3278, 3051, 2946, 2342, 2117, 1917, 1712, 1661, 1589, 1524, 1432, 1310, 1252, 1109, 973, 876, 790, 467 
690; HRMS (ESI): m/z calcd for C29H29N3O5 Na [M + Na]+ 522.2005; found: 522.1996. 468 
 469 
4.3.5. 1H NMR and 13C NMR spectra of Methyl (S)-3'-(2-amino-3-(1H-indol-3-yl)propanamido)-[1,1'-biphenyl]-3-carboxylate 470 
(14) 471 
 472 
The title compound 14 was prepared via protocol 4 using 12 (1.4 g, 2.72 mmol) to yield an off-white solid (1.00 g, 89%); m.p.: 473 
86.4–86.7 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.06 (s, 1H), 10.73 (s, 1H), 8.33 (br s, 2H), 8.16-8.15 (m, 1H), 8.00-7.97 (m, 474 
1H), 7.92-7.89 (m, 1H), 7.86-7.85 (m, 1H), 7.68-7.60 (m, 3H), 7.48-7.46 (m, 2H), 7.36 (d, J = 8.00 Hz, 1H), 7.26 (d, J = 4.00 Hz, 475 
1H), 7.09-7.05 (m, 1H), 6.98-6.94 (m, 1H), 4.21 (br s, 1H), 3.89 (s, 3H), 3.40-3.25 (m, 2H); 13C NMR (100 MHz, DMSO-d6): δ 476 
167.9, 166.6, 140.7, 140.1, 139.2, 136.7, 131.9, 130.9, 130.3, 130.1, 128.8, 127.5, 127.4, 125.4, 123.0, 121.7, 119.7, 119.0,  118.9, 477 
118.4, 111.9, 107.1, 54.1, 52.8, 27.8; IR (ATR): νmax 3282, 3054, 2947, 2341, 2106, 1911, 1713, 1663, 1589, 1525, 1433, 1310, 478 
1253, 1110, 974, 877, 791, 691; HRMS (ESI): m/z calcd for C25H23N3O3 [M + H]+: 413.1739; found 414.1810. 479 
 480 
4.3.6. 1H NMR and 13C NMR spectra of Methyl 3'-((S)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-3-(1H-indol-481 
3-yl)propanamido)-[1,1'-biphenyl]-3-carboxylate (16) 482 
 483 
The title compound  was prepared via protocol 1 using 14 and 15 (1.0 g, 3.76 mmol) to afford the coupled product 16 as an off-484 
white solid; m.p.: 116.3–117.2 °C;  1H NMR (400 MHz, DMSO-d6): δ 10.85 (s, 1H), 10.20 (s, 1H), 8.16-8.14 (m, 2H), 7.98-7.95 485 
(m, 1H), 7.90-7.88 (m, 2H), 7.66-7.62 (m, 3H), 7.44-7.38 (m, 2H), 7.32 (d, J = 8.00 Hz, 1H), 7.21-7.11 (m, 6H), 7.07-7.03 (m, 486 
1H), 6.95 (dd, J = 8.00, 14.00 Hz, 2H), 4.75 (q, J = 8.00 Hz, 1H), 4.22-4.16 (m, 1H), 3.89 (s, 3H), 3.24 (dd, J = 8.00, 16.00 Hz, 487 
1H), 3.12 (dd, J = 8.00, 14.00 Hz, 1H), 2.93 (dd, J = 4.00, 12.00 Hz, 1H), 2.75-2.69 (m, 1H), 1.28 (s, 9H); 13C NMR (100 MHz, 488 
DMSO-d6): δ 171.9, 170.9, 166.6, 155.7, 140.9, 139.9, 138.4, 136.5, 131.8, 130.8, 130.1, 130.0, 129.7, 128.7, 128.4, 127.8, 127.4, 489 
126.6, 124.1, 122.3, 121.4, 119.4, 119.0, 118.7, 118.1, 111.7, 110.0, 78.7, 56.4, 54.7, 52.8, 37.9, 28.6, 28.4; IR (ATR).νmax 3293, 490 
3055, 2320, 2096, 1649, 1492, 1433, 1310, 1250, 1259, 1110, 1012, 882; HRMS (ESI): m/z calcd for C39H40N4O6 [M + H]+: 491 
683.2846; found: 683.2841. 492 
 493 
4.3.7. 1H NMR and 13C NMR spectra of 3'-((S)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-3-(1H-indol-3-494 
yl)propanamido)-[1,1'-biphenyl]-3-carboxylic acid (17) 495 
 496 
To a solution of 16 (1.2 g, 2.33 mmol) in THF (10.0 mL) and MeOH (10.0 mL), was added a 1N NaOH(aq) (4.66 mL, 4.66 mmol) 497 
and stirred at room temperature for 16 h. Ethyl acetate was added and the layers were separated. The aqueous layer was then 498 
acidified with 1N HCl and then extracted with CH2Cl2 (2 X 100 mL) and then the solvent was removed under reduced pressure to 499 
yield 17 (1.05 g, 90%) as an off-white solid; m.p.: 172.6–173.6 °C;  1H NMR (400 MHz, DMSO-d6): δ 13.08 (br s, 1H), 10.84 (s, 500 
1H), 10.20 (s, 1H), 8.16-8.14 (m, 2H), 7.96-7.85 (m, 3H), 7.69-7.58 (m, 3H), 7.44-7.38 (m, 2H), 7.32 (d, J = 4.00 Hz, 1H), 7.21-501 
7.10 (m, 6H), 7.08-7.03 (m, 1H), 6.96 (dd, J = 8.00, 12.00 Hz, 2H), 4.75 (q, J = 8.00 Hz, 1H), 4.21-4.16 (m, 1H), 3.26-3.21 (m, 502 
1H), 3.14-3.10 (m, 1H), 2.95-2.90 (m, 1H), 2.75-2.69 (m, 1H), 1.28 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 171.9, 170.8, 503 
167.7, 155.7, 140.7, 140.1, 140.0, 138.4, 136.5, 132.0, 131.4, 130.0, 138.4, 136.5, 132.0, 131.3, 130.0, 129.8, 129.6, 128.8,  128.4, 504 
127.8, 127.6, 126.6, 126.6, 124.1, 122.2, 121.4, 119.3, 119.0, 118.7, 118.1, 111.7, 110.0, 78.7, 56.4, 54.7, 37.9, 28.6, 28.4; IR 505 
(ATR).νmax 2048, 1653, 1492, 1434, 1391, 1228, 1158, 1058, 849; HRMS (ESI): m/z calcd for C38H38N4O6Na [M + Na]+: 506 
669.2689; found: 669.2689. 507 
 508 
4.3.8. 1H NMR and 13C NMR spectra of 1-(2-aminoethyl)2,3-Bis(tert-butoxycarbonyl)guanidine (18b) 509 
 510 
The title compound 18b was prepared by adding the solution of N,N'-bis-(Boc)-1H-Pyrazole-1-carboxamidine (2 g, 6.45 mmol) in 511 
THF (50 ml) dropwise to ethylene diamine (4 ml, 59.6 mmol) in THF (100 ml). After 30 min of mixing at room temperature 512 
solvent was evaporated then toluene (100 ml) was added and evaporated in order to remove remaining traces of the ethylene 513 
diamine.The crude reaction mixture taken for next step due to the instability of the compound.1H NMR (400 MHz, CDCl3): δ 514 
11.50 (br s, 1H), 8.63 (br s, 1H), 3.47 (q, J = 4.00 Hz, 2H), 2.87 (t, J = 4.00 Hz, 2H), 1.49 (s, 9H), 1.48 (s, 9H); 13C NMR (100 515 
MHz, CDCl3): δ 163.6, 156.5, 153.2, 83.1, 79.3, 43.4, 41.0, 28.3, 28.1; IR (ATR).νmax 3385, 3068, 2972, 2887, 2807, 1613, 516 
1519, 1463, 1347, 1311, 1249, 1090, 1161, 884, 799. 517 
 518 
4.3.9. 1H NMR and 13C NMR spectra of Methyl Nw-((4-methoxy-2,3,6-trimethylphenyl)sulfonyl)-L-argininate (18d) 519 
 520 
The title compound 18d was prepared via protocol 3 using 20a (0.9 g, 1.44 mmol) to yield the desired product as an off-white 521 
solid (450 mg, 77%); m.p.: 136.3–137.3 °C; 1H NMR (400 MHz, CDCl3): δ 6.50 (s, 1H), 6.46 (br s, 1H), 6.38 (br s, 2H), 3.80 (s, 522 
3H), 3.67 (s, 3H), 3.47-3.45 (m, 1H), 3.15 (br s, 2H), 2.65 (s, 3H), 2.97 (s, 3H), 2.10 (s, 3H), 1.74-1.55 (m, 4H); 13C NMR (100 523 







(ATR).νmax 3428, 3329, 2934, 1733, 1541, 1459, 1398, 1246, 1303, 1098, 1016, 911, 802; HRMS (ESI): m/z calcd for 525 
C17H28N4O5S [M + H]+: 401.1780; found: 401.1851. 526 
 527 
4.3.10.1H NMR and 13C NMR spectra of tert-butyl (S)-(5-amino-6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-6-528 
oxohexyl)carbamate (18e) 529 
 530 
The title compound was prepared via protocol 3, using 20a (630 mg, 1.03 mmol) to yield the desired product 18e as an off-white 531 
solid (0.32 g, 80%); m.p.: 206.2–207.5 °C;  1H NMR (600 MHz, CDCl3): δ 7.63 (s, 1H), 5.09 (s, 1H), 4.67 (s, 1H), 3.34-3.08 (m, 532 
6H), 1.84-1.76 (m, 1H), 1.50-1.46 (m, 2H), 1.42 (s, 18H), 1.37-1.36 (m, 3H); 13C NMR (100 MHz, CDCl3): δ 175.6, 156.5, 156.1, 533 
79.4,79.1, 55.0, 40.6, 40.1, 39.7, 34.4, 29.8, 28.4, 28.4, 22.8; IR (ATR).νmax 3313, 2930, 1683, 1518, 1452, 1246, 1162, 994, 534 
859, 779; HRMS (ESI): m/z calcd for C18H36N4O5 [M + H]+: 389.2686; found: 389.2759. 535 
 536 
4.3.11. 1H NMR and 13C NMR spectra of tert-butyl (S)-(5-amino-6-((2-(2,3-dibocguanidino)ethyl)amino)-6-oxohexyl)carbamate 537 
(18f) 538 
 539 
The title compound was prepared via protocol 3, using 20b (850 mg, 1.07 mmol) to yield the desired product 18f as an off-white 540 
solid (0.45 g, 79%); m.p.: 184.4–185.6 °C; 1H NMR (400 MHz, CDCl3): δ 11.43 (s, 1H), 8.56 (t, J = 4.00 Hz, 1H), 7.91 (t, J = 541 
8.00 Hz, 1H), 4.59 (br s, 1H), 3.59-3.55 (m, 2H), 3.45-3.41 (m, 2H), 3.33-3.30 (m, 1H), 3.13-3.08 (m, 2H), 1.82-1.77 (m, 1H), 542 
1.52-1.51 (m, 1H), 1.49 (s, 18H), 1.49-1.45 (m, 4H), 1.43 (s, 9H), 1.39-1.37 (m, 2H); 13C NMR (100 MHz, CDCl3): δ 175.6, 543 
163.2, 157.1, 156.0, 153.1, 83.4, 79.5, 55.4, 40.2, 40.1, 40.0, 34.8, 30.0, 34.8, 30.0, 28.4, 28.3, 28.1, 23.0; IR (ATR).νmax  3326, 544 
2931, 1714, 1612, 1521, 1409, 1362, 1324, 1246, 1128, 1047, 854; HRMS (ESI): m/z calcd for C24H46N6O7 [M + H]+: 531.3428; 545 
found: 531.3500. 546 
 547 
4.3.12. 1H NMR and 13C NMR spectra of (S)-2-amino-N-(2-(2,3-dibocguanidino)ethyl)-5-(3-((4-methoxy-2,3,6-548 
trimethylphenyl)sulfonyl)guanidino)pentanamide (18g) 549 
 550 
The title compound was prepared via protocol 3, using 21b (730 mg, 0.82 mmol) to yield the desired product 18g as an off-white 551 
solid (0.48 g, 87%); m.p.: 102.2–103.6 °C; 1H NMR (400 MHz, CDCl3): δ 11.39 (br s, 1H), 8.56 (br s, 1H), 8.04 (t, J = 4.00 Hz, 552 
1H), 6.51 (s, 1H), 6.26 (br s, 3H), 3.81 (s, 3H), 3.54-3.39 (m, 5H), 3.24-3.20 (m, 2H), 2.67 (s, 3H), 2.60 (s, 3H), 2.11 (s, 3H), 553 
1.76-1.61 (m, 4H), 1.46 (s, 9H), 1.45 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 175.1, 163.0, 158.4, 157.1, 156.4, 153.0, 138.5, 554 
136.6, 133.6, 124.7, 111.7, 83.6, 79.8, 55.4, 54.3, 40.1, 31.7, 28.3, 28.0, 25.2, 24.1, 18.3, 11.9; IR (ATR).νmax 3326, 1719,  1611, 555 
1543, 1439, 1409, 1326, 1248, 1115, 1046, 839, 803; HRMS (ESI): m/z calcd for C29H50N8O8S [M + H]+: 671.3540; found: 556 
671.3540. 557 
 558 
4.3.13. 1H NMR and 13C NMR spectra of Methyl N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-Nw-((4-methoxy-2,3,6-559 
trimethylphenyl)sulfonyl)-L-argininate (20’) 560 
 561 
The title compound 20’ was prepared by adding thionyl chloride (0.23 mL, 3.28 mmol) dropwise to Nα-Fmoc-Nω-MTR-L-arginine 562 
(1.0 g, 1.64 mmol) in methanol (20.0 mL) at 0° C and then stirred at room temperature for 16 h. The solvents were removed and 563 
reduced pressure and the residue was diluted with ethylacetate (100.0 mL) and washed with saturated NaHCO3(40 mL), saturated 564 
brine (40 mL), then dried (Na2SO4) and concentrated under reduced pressure to afford a white solid (0.95 g, 93%); m.p.: 94.0–565 
94.4 °C; 1H NMR (400 MHz, CDCl3): δ 7.76-7.35 (m, 7H), 7.30 – 7.28 (m, 2H), 6.50 (s, 1H), 6.20 (br s, 2H), 5.74 – 5.72 (br d, J 566 
= 7.2 Hz), 4.38-4.29 (m, 2H), 4.19-4.14 (m, 2H), 3.79 (s, 3H), 3.71 (s, 3H), 3.22-3.21 (m, 2H), 2.69 (s, 3H), 2.62 (s, 3H), 2.11 (s, 567 
3H), 1.70-1.57 (m, 4H); 13C NMR (100 MHz, CDCl3): δ 172.7, 158.5, 156.3, 143.7, 143.6, 141.2, 138.5, 136.5, 133.5, 127.8, 568 
127.1, 125.1, 124.8, 120.0, 111.7, 67.13, 55.4, 52.6, 47.1, 40.7, 30.1, 25.2, 24.1, 18.3, 17.9, 11.9; IR (ATR).νmax 2946, 1717, 569 
1542, 1616, 1445, 1244, 1169, 1102; HRMS (ESI): m/z calcd for C32H38N4O7SNa [M + Na]+: 645.2359; found: 645.2356. 570 
 571 
4.3.14. 1H NMR and 13C NMR spectra of (9H-fluoren-9-yl)methyl (S)-(1-((2-(2,3-diboc guanidino)ethyl)amino)-5-(3-((4-methoxy-572 
2,3,6-trimethylphenyl)sulfonyl)guanidino)-1-oxopentan-2-yl)carbamate (20b) 573 
 574 
The title compound 20b was prepared from compound 18b (0.5 g, 1.64 mmol) and Nα-Fmoc-Nω-MTR-L-arginine (1.0 g, 1.64 575 
mmol) according to the protocol 2. Off-white solid (0.73 g, 50%); m.p.: 148.0–148.6 °C; 1H NMR (400 MHz, CDCl3): δ 11.40 (br 576 
s, 1H), 8.61 (br s, 1H), 7.98 (br s, 1H), 7.73 (d, J = 8.00 Hz, 2H), 7.57 (d, J = 8.00 Hz, 2H), 7.36 (t, J = 8.00 Hz, 2H), 7.30-7.24 577 
(m, 2H), 6.50 (br s, 1H), 6.23 (br s, 2H), 5.99 (d, J = 8.00 Hz, 1H), 4.34-4.22 (m, 2H), 4.18-4.14 (m, 2H), 3.79 (s, 3H), 3.54-3.15 578 
(m, 7H), 2.67 (s, 3H), 2.60 (s, 3H), 2.10 (s, 3H), 1.84-1.57 (m, 4H), 1.45 (s, 18H); 13C NMR (100 MHz, CDCl3): δ 163.3, 162.8, 579 
159.7, 158.5, 157.2, 156.4, 156.3, 153.0, 143.8, 143.8, 141.3, 138.6, 136.6, 133.4, 127.7, 127.1, 125.2, 124.8, 120.0, 83.6, 80.4, 580 
80.1, 67.1, 55.4, 47.1, 42.1, 40.1, 28.2, 28.2, 28.0, 25.2, 24.1, 18.4, 12.0; IR (ATR).νmax 3324, 2976, 2064, 1717, 1615, 1543, 581 
1446, 1304, 1248, 1117, 840; HRMS (ESI): m/z calcd for C44H60N8O10S [M + H]+: 893.4153; found: 893.4224. 582 
 583 
4.3.15. 1H NMR and 13C NMR spectra of (9H-fluoren-9-yl)methyl tert-butyl (6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-6-584 
oxohexane-1,5-diyl)(S)-dicarbamate (21a) 585 
 586 
The title compound 21a was prepared from compound 18a (0.34 g, 2.13 mmol) and Nα-Fmoc-Nε-Boc-L-lysine (1.0 g, 2.13 mmol) 587 
according to the protocol 2. Off-white solid (0.65 g, 50%); m.p.: 173.7–175.2 °C; 1H NMR (600 MHz, DMSO-d6): δ 7.90-7.87 588 







4.24-4.20 (m, 2H), 3.88-3.87 (m, 1H), 3.12-3.00 (m, 2H), 2.99-2.96 (m, 2H), 2.90-2.86 (m, 2H), 1.74-1.46 (m, 3H), 1.36 (s, 18H), 590 
1.28-1.19 (m, 3H); 13C NMR (150 MHz, DMSO-d6): δ 172.5, 156.4, 156.1, 156.0, 144.4, 144.2, 141.2, 128.1, 127.5, 125.7, 120.6, 591 
79.6, 79.4, 79.2, 79.2, 78.2, 77.8, 66.1, 55.2, 47.1, 46.3, 46.3, 32.1, 29.7, 28.7, 28.6, 26.4, 26.3, 23.3; IR (ATR).νmax 3356, 2943, 592 
2265, 2106, 1526, 1447, 1389, 1526, 1240, 1167, 1025, 836, 735; HRMS (ESI): m/z calcd for C33H46N4O7Na [M + Na]+: 593 
633.3264; found: 633.3261. 594 
 595 
4.3.16. 1H NMR and 13C NMR spectra of (9H-fluoren-9-yl)methyl tert-butyl (6-((2-(2,3-dibocguanidino)ethyl)amino)-6-596 
oxohexane-1,5-diyl)(S)-dicarbamate (21b) 597 
 598 
The title compound 21b was prepared from compound 18b (0.643 g, 2.13 mmol) and Nα-Fmoc-Nε-Boc-L-lysine (1.0 g, 2.13 599 
mmol) according to the protocol 2. Off-white solid (0.89 g, 55%); m.p.: 102.2–103.6 °C; 1H NMR (400 MHz, CDCl3): δ 11.43 (s, 600 
1H), 8.65 (br s, 1H), 8.07 (br s, 1H), 7.75 (d, J = 8.00 Hz, 2H), 7.59 (d, J = 8.00 Hz, 2H), 7.39 (t, J = 8.00 Hz, 2H), 7.33-7.26 (m, 601 
2H), 5.65 (d, J = 4.00 Hz, 1H), 4.59 (br s, 1H), 4.38-4.36 (m, 1H), 4.22-4.17 (m, 1H), 3.57-3.53 (m, 2H), 3.45-3.42 (m, 2H), 3.10-602 
3.08 (m, 2H), 1.87-1.80 (m, 1H), 1.70-1.66 (m, 1H), 1.50 (s, 9H), 1.48 (s, 9H), 1.42 (s, 9H), 1.48-1.32 (m, 6H); 13C NMR (100 603 
MHz, CDCl3): δ 171.6, 162.8, 157.6, 156.0, 155.9, 153.0, 143.9, 141.3, 127.7, 127.0, 125.2, 120.0, 83.7, 80 .0, 79.1, 66.9, 54.8, 604 
47.2, 41.5, 40.3, 32.9, 29.8, 28.4, 28.3, 28.0, 22.3; IR (ATR).νmax 3316, 2973, 1713, 1612, 1516, 1448, 1410, 1325, 1244, 1129, 605 
1046, 857; HRMS (ESI): m/z calcd for C39H56N6O9Na [M + Na]+: 775.4006; found: 775.4006. 606 
 607 
4.3.17. 1H NMR and 13C NMR spectra of tert-butyl (S)-(1-((3'-((2-((tert-butoxycarbonyl)amino)ethyl)carbamoyl)-[1,1'-biphenyl]-608 
3-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamate (22a) 609 
 610 
The title compound was prepared from compound 13 (100 mg, 0.20 mmol) and 18a (32 mg, 0.20 mmol) following the general 611 
protocol 1 to afford 22a as an off-white solid (83 mg, 65%).1H NMR (400 MHz, DMSO-d6):  δ 10.82 (br s, 1H), 10.20 (br s, 1H), 612 
8.60 (t, J = 4.00 Hz, 1H), 8.10 (s, 1H), 7.90 (br s, 1H), 7.85 (d, J = 4.00 Hz, 1H), 7.75 (d, J = 8.00 Hz, 1H), 7.67 (d, J = 8.00 Hz, 613 
2H), 7.57 (t, J = 8.00 Hz, 1H), 7.46-7.40 (m, 2H), 7.33 (d, J = 4.00 Hz, 1H), 7.20 (s, 1H), 7.08-6.92 (m, 4H), 4.44-4.40 (m, 1H), 614 
3.18-2.99 (m, 6H), 1.37 (s, 18H); 13C NMR (100 MHz, DMSO-d6): δ 166.7, 156.2, 140.6, 140.6, 136.5, 135.7, 129.8, 129.4, 615 
127.8, 126.9, 125.9, 124.3, 122.3, 121.3, 119.2, 119.1, 118.7, 118.3, 111.8, 110.4, 79.6, 78.6, 78.2, 28.7, 28.6, 28.3; IR 616 
(ATR).νmax 3298, 2974, 1669, 1492, 1453, 1247, 1158, 1010, 853; HRMS (ESI): m/z calcd for C36H43N5O6Na [M + Na]+: 617 
664.3111; found: 664.3102. 618 
 619 
4.3.18. 1H NMR and 13C NMR spectra of tert-butyl (S)-(1-((3'-((2-(2,3-dibocguanidino)ethyl)carbamoyl)-[1,1'-biphenyl]-3-620 
yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamate (22b) 621 
 622 
The title compound was prepared from compound 13 (100 mg, 0.20 mmol) and 18b (61 mg, 0.2 mmol) following the general 623 
protocol 1 to afford 22b as an off-white solid (94 mg, 60%); m.p.: 127.2–127.6 °C; 1H NMR (600 MHz, DMSO-d6): δ 11.49 (br s, 624 
1H), 10.81 (br s, 1H), 10.15 (br s, 1H), 8.67 (t, J = 6.00 Hz, 1H), 8.47 (t, J = 6.00 Hz, 1H), 8.08 (br s, 1H), 7.91 (s, 1H), 7.82 (d, J 625 
= 12.00 Hz, 1H), 7.75 (d, J = 12.00 Hz, 1H), 7.67-7.66 (m, 2H), 7.56 (t, J = 6.00 Hz, 1H), 7.32 (d, J = 6.00 Hz, 1H), 7.19 (br s, 626 
1H), 7.05 (t, J = 6.00 Hz, 1H), 6.99-6.95 (m, 2H), 4.40 (q, J = 6.00 Hz, 1H), 3.52 (q, J = 6.00 Hz, 2H), 3.46 (q, J = 6.00 Hz, 2H), 627 
3.17-3.13 (m, 1H), 3.04-3.00 (m, 1H), 1.43 (s, 9H), 1.37 (s, 9H), 1.33 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 171.1, 166.9, 628 
163.7, 163.5, 156.2, 155.7, 152.3, 140.6, 140.5, 140.1, 136.5, 135.6, 129.8, 129.7, 129.4, 129.4, 127.7, 126.7, 125.9, 124.2,  122.2, 629 
121.3, 119.2, 119.0, 118.6, 118.2, 111.7, 110.4, 83.3, 78.6, 78.5, 67.4, 56.3, 40.5, 39.2, 31.7, 28.7, 28.6, 28.4, 28.2, 28; IR 630 
(ATR).νmax 2977, 1612, 1535, 1364, 1326, 1229, 1133, 875; HRMS (ESI): m/z calcd for C42H53N7O8 [M + H]+: 784.3956; found: 631 
784.4031. 632 
 633 
4.3.19. 1H NMR and 13C NMR spectra of methyl N6-(tert-butoxycarbonyl)-N2-(3'-((S)-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-634 
3-yl)propanamido)-[1,1'-biphenyl]-3-carbonyl)-L-lysinate (22c) 635 
 636 
The title compound was prepared from compound 13 (100 mg, 0.20 mmol) and 18c (52 mg, 0.2 mmol) following the general 637 
protocol 1 to afford 22c as an off-white solid (109 mg, 74%); m.p.: 235.5–236.1 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.82 (s, 638 
1H), 10.17 (s, 1H), 8.84 (d, J = 8.00 Hz, 1H), 8.14 (s, 1H), 7.91-7.88 (m, 2H), 7.79 (d, J = 8.00 Hz, 1H), 7.68 (t, J = 4.00 Hz, 1H), 639 
7.59 (t, J = 8.00 Hz, 1H), 7.47-7.41 (m, 2H), 7.32 (d, J = 8.00 Hz, 1H), 7.20 (s, 1H), 7.06 (t, J = 8.00 Hz, 1H), 7.00-6.97 (m, 2H), 640 
6.78 (t, J = 8.00 Hz, 1H), 4.47-4.38 (m, 2H), 3.66 (s, 3H), 3.17-2.89 (m, 4H), 1.81 (t, J = 8.00 Hz, 1H), 1.41-1.37 (m, 2H), 1.34 (s, 641 
18H), 1.24-1.18 (m, 2H); 13C NMR (100 MHz, DMSO-d6): δ173.2, 166.9, 156.0, 155.7, 140.7, 140.5, 140.1, 136.5, 134.8, 130.0, 642 
129.8, 129.4, 127.7, 127.1, 126.1, 124.2, 122.3, 121.3, 119.0, 118.6, 118.2, 111.7, 110.4, 79.6, 78.5, 77.8, 53.2, 52.3, 30.7 , 29.5, 643 
28.7, 28.6, 28.2, 23.5; IR (ATR).νmax 2929, 2312, 1992, 1671, 1521, 1433, 1363, 1228, 1160, 1010, 860; HRMS (ESI): m/z calcd 644 
for C41H51N5O8Na [M + Na]+: 764.3635; found: 764.3630. 645 
 646 
4.3.20. 1H NMR and 13C NMR spectra of Methyl N2-(3'-((S)-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanamido)-[1,1'-647 
biphenyl]-3-carbonyl)-Nw-((4-methoxy-2,3,6-trimethylphenyl)sulfonyl)-L-argininate (22d) 648 
 649 
The title compound was prepared from compound 13 (100 mg, 0.20 mmol) and 18d (80 mg, 0.2 mmol) following the general 650 
protocol 1 to afford 22d as an off-white solid (104 mg, 59%); m.p.: 172.2–173.1 °C; 1H NMR (600 MHz, DMSO-d6): δ 10.82 (s, 651 
1H), 10.17 (s, 1H), 8.88 (d, J = 12.00 Hz, 1H), 8.13 (br s, 1H), 7.92-7.88 (m, 2H), 7.79 (d, J = 12.00 Hz, 1H), 7.68-7.66 (m, 2H), 652 
7.60 (t, J = 6.00 Hz, 1H), 7.47-7.41 (m, 2H), 7.33 (d, J = 12.00 Hz, 1H), 7.19 (br s, 1H), 7.08-7.04 (m, 1H), 7.00-6.96 (m, 2H), 653 







2.02 (s, 3H), 1.82-1.74 (m, 2H), 1.52-1.49 (m, 2H), 1.34 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 173.0, 171.8, 166.9, 157.9, 655 
156.6, 155.7, 140.7, 140.5, 140.1, 138.1, 136.5, 134.8, 130.1, 129.8, 129.5, 127.7, 127.1, 126.1, 124.3, 122.3, 121.3, 119.2, 119.1, 656 
118.6, 118.3, 112.2, 111.8, 110.4, 79.6, 78.6, 56.3, 55.9, 53.0, 52.3, 28.6, 28.4, 24.1, 18.5, 12.2; IR (ATR).νmax 3305, 2932 , 657 
1669, 1541, 1456, 1364, 1303, 1227, 1159, 1114, 1013; HRMS (ESI): m/z calcd for C46H55N7O9S [M + H]+: 882.3782; found: 658 
882.3854. 659 
4.3.21. 1H NMR and 13C NMR spectra of tert-butyl ((S)-5-(3'-((S)-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-660 
yl)propanamido)-[1,1'-biphenyl]-3-carboxamido)-6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-6-oxohexyl)carbamate (22e) 661 
 662 
The title compound was prepared from compound 13 (100 mg, 0.20 mmol) and 18e (77 mg, 0.20 mmol) following the general 663 
protocol 1 to afford 22e as an off-white solid (139 mg, 80%); m.p.: 131.5–131.7 °C; 1H NMR (600 MHz, DMSO-d6): δ 10.82 (s, 664 
1H), 10.16 (s, 1H), 8.55 (d, J = 6.00 Hz, 1H), 8.16 (s, 1H), 8.01 (t, J = 6.00 Hz, 1H), 7.92-7.91 (m, 2H), 7.77-7.75 (m, 1H), 7.68-665 
7.67 (m, 1H), 7.57 (t, J = 12.00 Hz, 1H), 7.45-7.43 (m, 2H), 7.32 (d, J = 6.00 Hz, 1H), 7.20 (s, 1H), 7.06 (t, J = 6.00 Hz, 1H), 666 
6.99-6.96 (m, 2H), 6.77-6.74 (m, 2H), 4.43-4.37 (m, 2H), 3.18-2.86 (m, 8H), 1.77-1.68 (m, 2H), 1.37-1.36 (m, 2H), 1.36 (s, 9H), 667 
1.34 (s, 18H), 1.24-1.15 (m, 2H); 13C NMR (150 MHz, DMSO-d6): δ 172.4, 171.8, 166.7, 156.1, 156.0, 155.8, 140.6, 140.6, 668 
136.5,135.3, 129.8, 129.3, 127.7, 127.2, 126.3, 124.3, 121.3, 119.2, 119.1, 118.7, 118.3, 111.7, 110.4, 78.6, 78.1, 77.7, 56.3, 54.1, 669 
40.5, 39.3, 31.8, 31.4, 29.7, 23.7, 22.5; IR (ATR).νmax 2972, 2930, 1683, 1521, 1455, 1246, 1163, 1010, 861; HRMS (ESI): m/z 670 
calcd for C47H63N7O9Na [M + Na]+: 892.4585; found: 892.4575. 671 
 672 
4.3.22. 1H NMR and 13C NMR spectra of (S)-3'-(2-amino-3-(1H-indol-3-yl)propanamido)-N-(2-aminoethyl)-[1,1'-biphenyl]-3-673 
carboxamide (23a) 674 
 675 
The title compound was prepared from compound 22a (75 mg, 0.116 mmol) following the general protocol 4 to afford 23a as a 676 
white solid (45 mg, 89%); m.p.: 164.5–164.7 °C; 1H NMR (600 MHz, DMSO-d6): δ 11.06 (d, J = 6.00 Hz, 1H), 10.70 (s, 1H), 677 
8.78 (t, J = 6.00 Hz, 1H), 8.30 (br s, 3H), 8.13 (t, J = 6.00 Hz, 1H), 7.90-7.87 (m, 5H), 7.79-7.77 (m, 1H), 7.68 (d, J = 12.00 Hz, 678 
1H), 7.62-7.60 (m, 2H), 7.50-7.49 (m, 2H), 7.37 (d, J = 12.00 Hz, 1H), 7.26 (d, J = 6.00 Hz, 1H), 7.10-7.07 (m, 1H), 6.99-6.97 679 
(m, 1H), 4.21-4.20 (m, 1H), 3.55 (q, J = 6.00 Hz, 2H), 3.39-3.35 (m, 2H), 3.28-3.25 (m, 2H), 3.03 (q, J = 6.00 Hz, 2H); 13C NMR 680 
(150 MHz, DMSO-d6): δ 167.9, 167.2, 140.6, 140.4, 139.1, 136.7, 135.3, 130.1, 129.9, 129.6, 127.5, 127.1, 126.1, 125.4, 123.1, 681 
121.7, 119.6, 119.0, 118.9, 118.5, 111.9, 107.1, 54.1, 40.5, 39.1, 37.6, 27.8; IR (ATR).νmax 3041, 2890, 1774, 1664, 1525, 1429, 682 
1318, 1179, 835, 795, 744; HRMS (ESI): m/z calcd for C26H27N5O2 [M + H]+: 442.2165; found: 442.2234. 683 
 684 
4.3.23. 1H NMR and 13C NMR spectra of (S)-3'-(2-amino-3-(1H-indol-3-yl)propanamido)-N-(2-guanidinoethyl)-[1,1'-biphenyl]-3-685 
carboxamide (23b) 686 
 687 
The title compound was prepared from compound 22b (90 mg, 0.122 mmol) following the general protocol 4 to afford 23b as a 688 
white solid (29 mg, 50%); m.p.: 236.7–238.0 °C;  1H NMR (600 MHz, DMSO-d6): δ 11.05 (br s, 1H), 10.69 (s, 1H), 8.77 (t, J = 689 
6.00 Hz, 1H), 8.28 (br s, 3H), 8.12 (t, J = 6.00 Hz, 1H), 7.89-7.87 (m, 2H), 7.78-7.77 (m, 1H), 7.70-7.67 (m, 2H), 7.62-7.59 (m, 690 
2H), 7.49-7.48 (m, 3H), 7.38-7.36 (m, 2H), 7.26 (d, J = 6.00 Hz, 2H), 7.10-7.07 (m, 1H), 6.99-6.97 (m, 1H), 4.20 (t, J = 6.00 Hz, 691 
1H), 3.45 (q, J = 6.00 Hz, 2H), 3.39-3.36 (m, 1H), 3.28-3.24 (m, 1H); 13C NMR (150 MHz, DMSO-d6): δ 167.9, 167.1, 157.5, 692 
140.6, 140.4, 139.1, 135.3, 130.1, 129.8, 129.6, 127.5, 126.9, 126.0, 125.4, 123.1, 121.7, 119.6, 119.0, 118.9, 118.5, 112.0,  693 
107.1,54.1, 40.8, 39.1, 27.8; IR (ATR).νmax 3178, 3080, 2340, 2110, 1657, 1542, 1430, 1316, 1200, 1148, 835, 797, 743; HRMS 694 
(ESI): m/z calcd for C27H29N7O2 [M + H]+: 484.2383; found: 484.2455. 695 
 696 
4.3.24. 1H NMR and 13C NMR spectra of Methyl (3'-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-[1,1'-biphenyl]-3-carbonyl)-L-697 
lysinate (23c) 698 
 699 
The title compound was prepared from compound 22c (50 mg, 0.067 mmol) following the general protocol 4 to afford 23c as a 700 
gummy solid (36 mg, 70%); 1H NMR (600 MHz, DMSO-d6): δ 11.00 (s, 1H), 10.70 (s, 1H), 8.89 (d, J = 6.00 Hz, 1H), 8.29 (br s, 701 
3H), 8.14-8.13 (m, 1H), 7.93-7.91 (m, 1H), 7.87-7.86 (m, 1H), 7.80-7.75 (m, 4H), 7.68 (d, J = 12.00 Hz, 1H), 7.62-7.60 (m, 2H), 702 
7.50-7.48 (m, 2H), 7.37-7.36 (m, 1H), 7.26 (d, J = 6.00 Hz, 1H), 7.10-7.07 (m, 1H), 6.99-6.97 (m, 1H), 4.50-4.46 (m, 1H), 4.20 703 
(br s, 1H), 3.67 (s,3H), 3.35-3.25 (m, 2H), 2.80-2.79 (m, 2H), 1.86-1.39 (m, 6H); 13C NMR (100 MHz, DMSO-d6): δ 173.1, 167.9, 704 
166.9, 158.6, 158.4, 140.6, 140.4, 139.1, 136.7, 134.8, 130.2, 130.1, 129.6, 127.5, 127.2, 126.2, 125.4, 123.2, 121.6, 119.6, 705 
118.95, 118.9, 118.6, 111.9, 107.1, 54.1, 53.0, 52.4, 40.5, 40.4, 39.0, 30.4, 27.8, 27.0, 23.1; IR (ATR).νmax 3251, 3044, 2932, 706 
2098, 1666, 1524, 1432, 1338, 1178, 1118, 835, 796, 743, 719; HRMS (ESI): m/z calcd for C31H35N5O4 [M + H]+: 542.2689; 707 
found: 542.2157. 708 
 709 
4.3.25. 1H NMR and 13C NMR spectra of Methyl (3'-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-[1,1'-biphenyl]-3-carbonyl)-L-710 
argininate (23d) 711 
 712 
The title compound was prepared from compound 22d (90 mg, 0.10 mmol) following the general protocol 4 to afford 23d as a 713 
gummy solid (50 mg, 54%).1H NMR (600 MHz, DMSO-d6): δ 11.04 (s, 1H), 10.66 (s, 1H), 8.93 (d, J = 6.00 Hz, 1H), 8.27 (br s, 714 
3H), 8.13 (br s, 1H), 7.92 (d, J = 6.00 Hz, 2H), 7.79 (d, J = 12.00 Hz, 1H), 7.73-7.45 (m, 6H), 7.38-7.25 (m, 2H), 7.10-6.97 (m, 715 
3H), 4.52-4.49 (m, 1H), 4.19-4.18 (m, 1H), 3.68 (s, 3H), 3.35-3.12 (m, 4H), 1.92-1.54 (m, 4H); 13C NMR (150 MHz, DMSO-d6): 716 
δ 172.9, 167.9, 166.9, 162.2, 158.7, 158.5, 157.2, 140.6, 140.4, 139.1, 136.7, 134.8, 130.2, 130.1, 129.6, 127.5, 127.2, 126.2, 717 







, 3192, 3065, 2118, 1660, 1539, 1434, 1315, 1227, 1159, 836, 797, 744; HRMS (ESI): m/z calcd for C31H35N7O4 [M + H]+: 719 
570.3114; found: 570.2820. 720 
 721 
4.3.26. 1H NMR and 13C NMR spectra of N-((S)-6-amino-1-((2-aminoethyl)amino)-1-oxohexan-2-yl)-3'-((S)-2-amino-3-(1H-indol-722 
3-yl)propanamido)-[1,1'-biphenyl]-3-carboxamide (23e) 723 
 724 
The title compound was prepared from compound 22c (100 mg, 0.114 mmol) following the general protocol 4 to afford 23e as a 725 
white solid (45 mg, 70%); m.p.: 237.6–238.0 °C; 1H NMR (600 MHz, DMSO-d6): δ 11.05 (d, J = 4.00 Hz, 1H), 10.71 (s, 1H), 726 
8.68 (d, J = 4.00 Hz, 1H), 8.29-8.23 (m, 4H), 8.16 (s, 1H), 7.94 (d, J = 4.00 Hz, 1H), 7.85 (br s, 4H), 7.77-7.75 (m, 4H), 7.67 (d, J 727 
= 8.00 Hz, 1H), 7.60-7.58 (m, 2H), 7.51-7.47 (m, 2H), 7.36 (d, J = 8.00 Hz, 1H), 7.25 (d, J = 4.00 Hz, 1H), 7.08 (t, J = 4.00 Hz, 728 
1H), 6.97 (t, J = 4.00 Hz, 1H), 4.44-4.41 (m, 1H), 4.21-4.20 (m, 1H), 3.37-3.24 (m, 4H), 2.88-2.77 (m, 4H), 1.86-1.70 (m, 2H), 729 
1.60-1.52 (m, 2H), 1.44-1.31 (m, 2H); 13C NMR (150 MHz, DMSO-d6): δ 172.8, 167.9, 166.8, 158.9, 158.7, 158.5, 140.7, 140.3, 730 
139.1, 136.7, 135.2, 130.0, 129.4, 127.5, 127.3, 126.3, 125.4, 123.2, 121.7, 119.6, 118.9, 118.6, 116.7, 111.9, 107.1, 54.1, 53.8, 731 
40.5, 39.1, 38.9, 36.9, 31.2, 27.8, 27.2, 23.2; IR (ATR).νmax 3257, 3052, 2930, 2099, 1664, 1524, 1431, 1317, 1170, 797, 744,  732 
720; HRMS (ESI): m/z calcd for C32H39N7O3 [M + H]+: 570.3114; found: 570.2820. 733 
 734 
4.3.27. 1H NMR and 13C NMR spectra of tert-butyl ((S)-1-(((S)-1-((3'-((2-((tert-butoxycarbonyl)amino)ethyl)carbamoyl)-[1,1'-735 
biphenyl]-3-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (24a) 736 
 737 
The title compound was prepared from compound 17 (100 mg, 0.15 mmol) and 18a (25 mg, 0.15 mmol) following the general 738 
protocol 1 to afford 24a as an off-white solid (94 mg, 80%); m.p.: 126.7–128.0 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.82 (s, 739 
1H), 10.15 (s, 1H), 8.57-8.56 (m, 1H), 8.43 (d, J = 8.00 Hz, 1H), 8.10 (s, 1H), 7.81-7.67 (m, 7H), 7.52 (t, J = 8.00 Hz, 1H), 7.30 740 
(d, J = 8.00 Hz, 1H), 7.17-6.91 (m, 9H), 6.76 (d, J = 8.00 Hz, 1H), 4.75 (q, J = 8.00 Hz, 1H), 4.26-4.21 (m, 1H), 3.29-3.03 (m, 741 
6H), 2.73-2.72 (m, 1H), 2.60-2.54 (m, 1H), 1.36 (s, 9H), 1.29 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 171.9, 166.7, 160.0, 742 
156.2, 155.7, 155.1, 140.0, 139.8, 138.9, 138.3, 137.1, 136.5, 135.6, 134.9, 129.7, 129.3, 129.3, 128.3, 127.7, 127.5, 126.5, 125.3, 743 
124.2, 121.4, 120.2, 119.0, 118.7, 111.7, 110.1, 78.5, 78.1, 56.0, 54.5, 37.8, 28.7, 28.5, 28.2; IR (ATR).νmax 3299, 2976, 1663, 744 
1518, 1455, 1246, 1160, 1118, 1021, 806; HRMS (ESI): m/z calcd for C45H52N6O7Na [M + Na]+: 811.3795; found: 811.3789. 745 
 746 
4.3.28. 1H NMR and 13C NMR spectra of tert-butyl ((S)-1-(((S)-1-((3'-((2-(2,3-dibocguanidino)ethyl)carbamoyl)-[1,1'-biphenyl]-747 
3-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (24b) 748 
 749 
The title compound was prepared from compound 17 (100 mg, 0.15 mmol) and 18b (46 mg, 0.15 mmol) following the general 750 
protocol 1 to afford 24b as an off-white solid (95 mg, 68%); m.p.: 206.3–206.5 °C;  1H NMR (600 MHz, DMSO-d6): δ 11.50 (s, 751 
1H), 10.80 (s, 1H), 10.20 (s, 1H), 8.41-8.45 (m, 1H), 8.14 (br s, 1H), 8.07 (br s, 1H), 7.88 (s, 1H), 7.82 (d, J = 4.00 Hz, 1H), 7.73 752 
(d, J = 4.00 Hz, 1H), 7.62 (t, J = 8.00 Hz, 2H), 7.55 (t, J = 4.00 Hz, 1H), 7.42-7.40 (m, 2H), 7.32-7.31(m, 1H), 7.20-7.13 (m, 7H), 753 
7.05 (t, J = 4.00 Hz, 1H), 6.97-6.92 (m, 2H), 4.75-4.74 (m, 1H), 4.18-4.17 (m, 1H), 3.50 (t, J = 4.00 Hz, 2H), 3.45 (q, J = 4.00 Hz, 754 
2H), 3.25-3.21 (m, 1H), 3.13-3.09 (m, 1H), 2.93-2.90 (m, 1H), 2.73-2.69 (m, 1H), 1.42 (s, 9H), 1.37 (s, 9H), 1.28 (s, 9H); 13C 755 
NMR (150 MHz, DMSO-d6): δ 171.9, 170.8, 166.9, 163.6, 156.2, 155.7, 152.3, 140.6, 140.5, 139.9, 138.4, 136.5, 135.7, 129.8, 756 
129.6, 129.4, 128.4, 127.8, 126.7, 126.6, 125.9, 124.1, 122.4, 121.4, 119.2, 118.9, 118.7, 118.3, 111.7, 110.0, 83.3, 78.6, 56.4, 757 
54.6, 40.5, 39.2, 37.9, 31.7, 28.7, 28.6, 28.0;  IR (ATR).νmax 2974, 1641, 1539, 1364, 1326, 1250, 1133, 1049, 876; HRMS 758 
(ESI): m/z calcd for C51H62N8O9Na [M + Na]+: 953.4537; found: 953.4533. 759 
 760 
4.3.29. 1H NMR and 13C NMR spectra of Methyl N6-(tert-butoxycarbonyl)-N2-(3'-((S)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-761 
phenylpropanamido)-3-(1H-indol-3-yl)propanamido)-[1,1'-biphenyl]-3-carbonyl)-L-lysinate (24c) 762 
 763 
The title compound was prepared from compound 17 (100 mg, 0.15 mmol) and 18c (39 mg, 0.15 mmol) following the general 764 
protocol 1 to afford 24c as an off-white solid (106 mg, 80%); m.p.: 132.5–133.9 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.85 (s, 765 
1H), 10.20 (s, 1H), 8.83 (d, J = 8.00 Hz, 1H), 8.16-8.12 (m, 2H), 7.90-7.88 (m, 2H), 7.76 (d, J = 8.00 Hz, 1H), 7.65-7.56 (m, 3H), 766 
7.46-7.43 (m, 2H), 7.32 (d, J = 8.00 Hz, 1H), 7.21-7.14 (m, 6H), 7.06 (t, J = 4.00 Hz, 1H), 6.99-6.93 (m, 2H), 6.78 (t, J = 4.00 Hz, 767 
1H), 4.76 (q, J = 8.00 Hz, 1H), 4.44 (q, J = 8.00 Hz, 1H), 4.22-4.16 (m, 1H), 3.66 (s, 3H), 3.27-3.21 (m, 1H), 3.15-3.09 (m, 1H), 768 
2.95-2.94 (m, 3H), 2.75-2.69 (m, 1H), 1.83-1.80 (m, 2H), 1.40-1.37 (m, 2H), 1.34 (s, 9H), 1.29 (s, 9H), 1.18-1.14 (m, 2H); 13C 769 
NMR (100 MHz, DMSO-d6): δ 173.2, 171.9, 170.8, 166.9, 156.0, 155.7, 140.6, 140.5, 139.8, 138.4, 136.5, 134.8, 130.0, 129.8, 770 
129.6, 129.5, 128.4, 127.8, 127.2, 126.6, 126.1, 124.1, 122.4, 121.4, 119.2, 118.9, 118.7, 118.3, 118.7, 118.3, 111.7, 110.0,  78.7, 771 
77.7, 56.4, 54.6, 53.2, 37.9, 31.4, 30.7, 29.6, 28.7, 28.6; IR (ATR).νmax 3305, 3047, 2925, 1652, 1509, 1453, 1363, 1245, 1161, 772 
1012, 855; HRMS (ESI): m/z calcd for C50H60N6O9Na[M + Na]+: 911.4319; found: 911.4316. 773 
 774 
4.3.30. 1H NMR and 13C NMR spectra of Methyl N2-(3'-((S)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)-3-(1H-775 
indol-3-yl)propanamido)-[1,1'-biphenyl]-3-carbonyl)-Nw-((4-methoxy-2,3,6-trimethylphenyl)sulfonyl)-L-argininate (24d) 776 
 777 
The title compound was prepared from compound 17 (100 mg, 0.15 mmol) and 18d (60 mg, 0.15 mmol) following the general 778 
protocol 1 to afford 24d as an off-white solid (115 mg, 75%); m.p.: 179.5–179.7 °C; 1H NMR (600 MHz, DMSO-d6): δ 10.85 (s, 779 
1H), 10.20 (s, 1H), 8.87 (d, J = 4.00 Hz, 1H), 8.15-8.12 (m, 2H), 7.89-7.88 (m, 2H), 7.77 (d, J = 4.00 Hz, 1H), 7.64-7.57 (m, 3H), 780 
7.45-7.41 (m, 2H), 7.33 (d, J = 4.00 Hz, 1H), 7.21-7.13 (m, 6H), 7.07-7.04 (m, 1H), 6.98-6.93 (m, 2H), 6.66 (br s, 2H), 4.75 (q, J 781 
= 4.00 Hz, 1H), 4.46-4.42 (m, 1H), 4.21-4.17 (m, 1H), 3.77 (s, 3H), 3.65 (s, 3H), 3.25-3.22 (m, 1H), 3.14-3.06 (m, 3H), 2.94-2.91 782 







DMSO-d6): δ 172.9, 171.9, 166.9, 157.9, 155.7, 140.7, 140.5, 139.8, 138.4, 138.1, 136.5, 136.0, 134.8, 130.1, 129.8, 129.6, 129.5, 784 
128.4, 127.8, 127.2, 126.6, 126.1, 124.1, 122.5, 121.4, 119.3, 118.9, 118.7, 118.3, 112.1, 111.7, 110.0, 79.6, 78.7, 56.4, 55 .9, 52.9, 785 
52.4, 40.5, 37.9, 28.6, 28.4, 24.1, 18.5, 12.1; IR (ATR).νmax 2931, 1649, 1541, 1454, 1363, 1304, 1227, 1158, 1114, 1013; 786 
HRMS (ESI): m/z calcd for C55H64N8O10S [M + H]+: 1029.4466; found: 1029.4540. 787 
4.3.31. 1H NMR and 13C NMR spectra of tert-butyl ((S)-1-(((S)-3-(1H-indol-3-yl)-1-oxo-1-((3'-(((S)-2,2,18,18-tetramethyl-4,9,16-788 
trioxo-3,17-dioxa-5,8,15-triazanonadecan-10-yl)carbamoyl)-[1,1'-biphenyl]-3-yl)amino)propan-2-yl)amino)-1-oxo-3-789 
phenylpropan-2-yl)carbamate (24e) 790 
 791 
The title compound was prepared from compound 17 (100 mg, 0.15 mmol) and 18e (58 mg, 0.15 mmol) following the general 792 
protocol 1 to afford 24e as an off-white solid (106 mg, 70%); m.p.: 131.9–132.4 °C; 1H NMR (600 MHz, DMSO-d6): δ 10.84 (s, 793 
1H), 10.19 (s, 1H), 8.53 (d, J = 6.00 Hz, 1H), 8.13 (br s, 2H), 8.00 (t, J = 6.00 Hz, 1H), 7.91-7.88 (m, 2H), 7.73 (d, J = 12.00 Hz, 794 
1H), 7.63-7.62 (m, 2H), 7.56 (t, J = 6.00 Hz, 1H), 7.44-7.42 (m, 2H), 7.31 (d, J = 12.00 Hz, 1H), 7.21-7.13 (m, 6H), 7.06-7.03 (m, 795 
1H), 6.97-6.92 (m, 2H), 6.76-6.73 (m, 2H), 4.75 (q, J = 6.00 Hz, 1H), 4.39-4.37 (m, 1H), 4.20-4.16 (m, 1H), 3.25-3.05 (m, 4H), 796 
3.00-2.86 (m, 5H), 2.73-2.69 (m, 1H), 1.75-1.67 (m, 2H), 1.34 (s, 9H), 1.33 (s, 9H), 1.28 (s, 9H), 1.16-1.13 (m, 2H), 0.96-0.94 (m, 797 
2H); 13C NMR (150 MHz, DMSO-d6): δ 172.4, 171.9, 170.8, 166.7, 156.1, 156.0, 155.7, 140.6, 140.5, 139.8, 138.4, 136.5, 135.3, 798 
129.8, 129.6, 129.3, 128.4, 127.8, 127.2, 126.6, 126.2, 124.1, 122.5, 121.4, 118.9, 118.3, 111.7, 110.0, 78.7, 78.1, 77.7, 56 .4, 54.6, 799 
54.0, 56.4, 54.6, 54.0, 40.5, 39.3, 37.9, 31.8, 29.7, 28.7, 28.6, 28.5, 23.6; IR (ATR).νmax 3292, 2973, 1650, 1510, 1453, 1247, 800 
1163, 1045, 856, 741; HRMS (ESI): m/z calcd for C56H72N8O10Na[M + Na]+: 1039.5269; found: 1039.5261. 801 
 802 
4.3.32. 1H NMR and 13C NMR spectra of tert-butyl ((S)-1-(((S)-1-((3'-(((S)-6-amino-1-((2-(2,3-dibocguanidino)ethyl)amino)-1-803 
oxohexan-2-yl)carbamoyl)-[1,1'-biphenyl]-3-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-804 
yl)carbamate (24f) 805 
 806 
The title compound was prepared from compound 17 (100 mg, 0.15 mmol) and 18f (80 mg, 0.15 mmol) following the general 807 
protocol 1 to afford 24f as an off-white solid (128 mg, 74%); m.p.: 192.5–194.0 °C; 1H NMR (600 MHz, DMSO-d6): δ 11.50 (s, 808 
1H), 10.80 (s, 1H), 10.19 (s, 1H), 8.52 (d, J = 12.00 Hz, 1H), 8.35 (t, J = 6.00 Hz, 1H), 8.13 (br s, 3H), 7.90-7.74 (m, 2H), 7.73 (d, 809 
J = 12.00 Hz, 1H), 7.64-7.62 (m, 2H), 7.55 (t, J = 12.00 Hz, 1H), 7.44-7.41 (m, 2H), 7.31 (d, J = 12.00 Hz, 1H), 7.20-7.12 (m, 810 
6H), 7.07-7.03 (m, 1H), 6.98-6.92 (m, 2H), 6.73 (t, J = 6.00 Hz, 1H), 4.75 (q, J = 6.00 Hz, 1H), 4.40 (q, J = 12.00 Hz, 1H), 4.20-811 
4.15 (m, 1H), 3.34-3.36 (m, 2H), 3.30-3.10 (m, 4H), 2.94-2.86 (m, 3H), 2.74-2.71 (m, 1H), 1.75-1.68 (m, 2H), 1.43 (s, 9H), 1.38 812 
(s, 9H), 1.37-1.34 (m, 2H), 1.28 (s, 9H), 1.32 (s, 9H); 13C NMR (150 MHz, DMSO-d6): δ 172.6, 172.0, 170.8, 166.5, 163.5, 156.1, 813 
155.7, 152.3, 151.8, 140.6, 140.5, 139.8, 136.5, 135.3, 129.8, 129.6, 129.3, 128.4, 127.8, 127.2, 126.6, 126.2, 124.1, 121.3,  119.3, 814 
118.9, 118.7,118.4, 111.7, 110.0, 83.3, 79.6, 78.6, 77.7, 56.4, 54.6, 54.1, 38.3, 31.9, 29.7, 28.7, 28.5, 28.4, 28.0, 23.6; IR 815 
(ATR).νmax 3284, 3066, 2973, 1635, 1540, 1363, 1322, 1247, 1131, 1022, 856, 741; HRMS (ESI): m/z calcd for 816 
C62H82N10O12Na[M + Na]+: 1181.6011; found: 1181.6010. 817 
 818 
4.3.33. 1H NMR and 13C NMR spectra of tert-butyl ((S)-1-(((S)-1-((3'-(((S)-1-((2-(2,3-dibocguanidino)ethyl)amino)-5-(3-((4-819 
methoxy-2,3,6-trimethylphenyl)sulfonyl)guanidino)-1-oxopentan-2-yl)carbamoyl)-[1,1'-biphenyl]-3-yl)amino)-3-(1H-indol-3-yl)-820 
1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (24g) 821 
 822 
The title compound was prepared from compound 17 (50 mg, 0.075 mmol) and 18g (50 mg, 0.15 mmol) following the general 823 
protocol 1 to afford 24g as a gummy solid (50 mg, 49%).1H NMR (600 MHz, DMSO-d6): δ 11.40 (s, 1H), 10.84 (s, 1H), 10.19 (s, 824 
1H), 8.56 (d, J = 12.00 Hz, 1H), 8.33 (t, J = 6.00 Hz, 1H), 8.18-8.14 (m, 3H), 7.91-7.89 (m, 2H), 7.75-7.89 (m, 2H), 7.74 (d, J = 825 
12.00 Hz, 1H), 7.69-7.62 (m, 2H), 7.56 (t, J = 12.00 Hz, 1H), 7.43-7.40 (m, 2H), 7.32 (d, J = 12.00 Hz, 1H), 7.21-7.09 (m, 6H), 826 
7.06 (t, J = 6.00 Hz, 1H), 6.95 (dd, J = 12.00, 24.00 Hz, 2H), 6.78-6.66 (m, 2H), 6.56-6.36 (m, 2H), 4.75 (q, J = 6.00 Hz, 1H), 827 
4.43 (q, J = 12.00 Hz, 1H), 4.21-4.15 (m, 1H), 3.75 (s, 3H), 3.27-3.05 (m, 8H), 2.94-2.90 (m, 1H), 2.74-2.68 (m, 1H), 2.57 (s, 828 
3H), 2.49 (s, 3H), 2.00 (s, 3H), 1.80-1.53 (m, 4H), 1.41 (s, 9H), 1.38 (s, 9H), 1.28 (s, 9H); 13C NMR (150 MHz, DMSO-d6): δ 829 
172.4, 170.8, 166.6, 163.5, 157.9, 156.6, 156.0, 152.3, 140.5, 140.53, 139.8, 138.4, 138.1, 136.5, 136.0, 135.1, 129.8, 129.6, 830 
129.3, 128.4, 127.7, 126.6, 126.2, 124.1, 121.4, 118.9, 112.1, 111.7, 110.0, 83.3, 79.6, 78.7, 56.4, 55.9, 54.6, 53.6, 40.5, 38.3, 831 
29.5, 28.5, 28.4, 28.0, 24.0, 18.4, 12; IR (ATR).νmax 3310, 2305, 2095, 1868, 1609, 1543, 1363, 1304, 1246, 1112, 740, 683; 832 
HRMS (ESI): m/z calcd for C67H86N12O13S [M + H]+: 1299.6158; found: 1299.6229. 833 
 834 
4.3.34. 1H NMR and 13C NMR spectra of 3'-((S)-2-((S)-2-amino-3-phenylpropanamido)-3-(1H-indol-3-yl)propanamido)-N-(2-835 
aminoethyl)-[1,1'-biphenyl]-3-carboxamide (25a) 836 
 837 
The title compound was prepared from compound 24a (80 mg, 0.101 mmol) following the general protocol 4 to afford 25a as a 838 
white solid (38 mg, 65%); m.p.: 206.9–207.5 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.86 (d, J = 4.00 Hz, 1H), 10.40 (s, 1H), 839 
8.94 (t, J = 4.00 Hz, 1H), 8.60 (d, J = 8.00 Hz, 1H), 8.27 (br s, 3H), 8.16 (br s, 1H), 7.84-7.83 (m, 2H), 7.76-7.67 (m, 5H), 7.55 (t, 840 
J = 16.00 Hz, 1H), 7.32 (d, J = 8.00 Hz, 1H), 7.20-7.05 (m, 6H), 7.02-6.98 (m, 3H), 4.77-4.76 (m, 2H), 3.70 (q, J = 4.00 Hz, 1H), 841 
3.54 (q, J = 8.00 Hz, 1H), 3.20-3.17 (m, 1H), 3.07-2.99 (m, 3H), 2.89-2.83 (m, 1H), 2.63-2.57 (m, 1H); 13C NMR (100 MHz, 842 
DMSO-d6): δ 172.3, 170.9, 167.2, 164.7, 140.1, 139.1, 137.6, 136.6, 135.2, 134.8, 129.8, 129.5, 129.4, 128.5, 127.7, 127.5, 126.8, 843 
125.5, 124.4, 121.4, 120.3, 119.1, 118.7, 111.8, 109.9, 55.3, 54.6, 39.1, 37.9, 28.6; IR (ATR).νmax 2919, 2848, 2250, 1654, 1537, 844 
1397, 1299, 1173, 1067, 743; HRMS (ESI): m/z calcd for C35H36N6O3 [M + H]+: 589.2849; found: 589.2911.   845 
 846 
4.3.35 1H NMR and 13C NMR spectra of 3'-((S)-2-((S)-2-amino-3-phenylpropanamido)-3-(1H-indol-3-yl)propanamido)-N-(2-847 








The title compound was prepared from compound 24b (80 mg, 0.08 mmol) following the general protocol 4 to afford 25b as a 850 
white gummy solid (27 mg, 49%).1H NMR (600 MHz, DMSO-d6): δ 10.89 (br s, 1H), 10.35 (br s, 1H), 8.94 (d, J = 4.00 Hz, 1H), 851 
8.75 (t, J = 4.00 Hz, 1H), 8.11-7.93 (m, 4H), 7.87-7.85 (m, 1H), 7.77-7.75 (m, 1H), 7.68 (d, J = 8.00 Hz, 1H), 7.63-7.58 (m, 4H), 852 
7.46-7.42 (m, 4H), 7.26-7.15 (m, 6H), 7.08-6.97 (m, 4H), 4.82 (q, J = 4.00 Hz, 1H), 4.07 (t, J = 4.00 Hz, 1H), 3.43 (q, J = 4.00 853 
Hz, 2H), 3.28-3.24 (m, 1H), 3.14-3.08 (m, 2H), 2.97-2.93 (m, 1H); 13C NMR (150 MHz, DMSO-d6): δ 169.8, 166.6, 158.1, 157.9, 854 
156.9, 140.2, 140.0, 139.3, 136.0, 134.8, 129.5, 129.4,129.41, 129.1, 128.4, 127.2, 127.0, 126.3, 125.5, 123.7, 122.1, 121.0, 118.9,  855 
118.4, 118.3, 117.8, 111.4, 109.2, 87.8, 54.5, 53.3, 40.3, 38.6, 37.1, 28.0; IR (ATR).νmax 3276, 3189, 3064, 1651, 1538, 1433 , 856 
1318, 1201, 1150, 836, 798, 742 HRMS (ESI): m/z calcd for C36H38N8O3 [M + H]+: 631.3067; found: 631.3141.  857 
 858 
4.3.36.1H NMR and 13C NMR spectra of Methyl (3'-((S)-2-((S)-2-amino-3-phenylpropanamido)-3-(1H-indol-3-yl)propanamido)-859 
[1,1'-biphenyl]-3-carbonyl)-L-lysinate (25c) 860 
 861 
The title compound was prepared from compound 24c (90 mg, 0.112 mmol) following the general protocol 4 to afford 25c as a 862 
white gummy solid (46 mg, 60%).1H NMR (600 MHz, DMSO-d6): δ 10.89 (br s, 1H), 10.35 (s, 1H), 8.94 (d, J = 4.00 Hz, 1H), 863 
8.87 (d, J = 8.00 Hz, 1H), 8.13-7.90 (m, 5H), 7.79-7.68 (m, 5H), 7.63-7.59 (m, 2H), 7.46-7.44 (m, 2H), 7.33 (d, J = 4.00 Hz, 1H), 864 
7.26-7.15 (m, 6H), 7.07-7.05 (m, 1H), 6.99-6.97 (m, 1H), 4.81 (q, J = 4.00 Hz, 1H), 4.49-4.45 (m, 1H), 4.07 (t, J = 4.00 Hz, 1H), 865 
3.66 (s, 3H), 3.28-3.24 (m, 1H), 3.14-3.09 (m, 2H), 2.99-2.94 (m, 1H), 2.79-2.77 (m, 2H), 1.85-1.80 (m, 2H), 1.60-1.53 (m, 2H), 866 
1.47-1.38 (m, 2H); 13C NMR (150 MHz, DMSO-d6): δ 173.1, 170.3, 168.6, 167.0, 158.5, 158.3, 140.6, 140.5, 139.9, 136.6, 135.2, 867 
134.8, 130.0, 130.0, 129.5, 128.9, 127.7, 127.5, 127.1, 126.2, 124.2, 122.6, 121.5, 119.4, 118.9, 118.8, 118.3, 111.8, 109.7,  55.0, 868 
53.7, 52.9, 52.4, 39.1, 37.6, 30.4, 28.5, 27.0, 23.1; IR (ATR).νmax 3276, 3195, 3081, 2109, 1540, 1433, 1318, 1198, 798, 743; 869 
HRMS (ESI): m/z calcd for C40H44N6O5 [M + H]+: 689.3373; found: 689.3448.  870 
 871 
4.3.37. 1H NMR and 13C NMR spectra of Methyl (3'-((S)-2-((S)-2-amino-3-phenylpropanamido)-3-(1H-indol-3-yl)propanamido)-872 
[1,1'-biphenyl]-3-carbonyl)-L-argininate (25d) 873 
 874 
The title compound was prepared from compound 24d (90 mg, 0.087 mmol) following the general protocol 4 to afford 25d as a 875 
brown gummy solid (25 mg, 40%).1H NMR (600 MHz, DMSO-d6): δ 10.89 (s, 1H), 10.35 (s, 1H), 8.94 (dd, J = 4.00, 12.00 Hz, 876 
2H), 8.13-8.12 (m, 4H), 7.93-7.90 (m, 2H), 7.79-7.78 (m, 1H), 7.69 (d, J = 8.00 Hz, 1H), 7.64-7.60 (m, 3H), 7.48-7.33 (m, 4H), 877 
7.27-7.16 (m, 7H), 7.08-7.06 (m, 1H), 7.00-6.98 (m, 1H), 4.82 (q, J = -4.00 Hz, 1H), 4.52-4.49 (m, 1H), 4.10 (br s, 1H), 3.67 (s, 878 
3H), 3.29-3.25 (m, 1H), 3.15-3.09 (m, 4H), 2.99-2.95 (m, 1H), 1.91-1.54 (m, 4H); 13C NMR (150 MHz, DMSO-d6): δ 172.9, 879 
170.3, 168.4, 166.9, 158.2, 157.2, 140.6, 140.4, 139.8, 136.6, 135.1, 134.8, 130.1, 130.0, 129.9, 129.5, 128.9, 129.6, 128.9,  127.7, 880 
126.1, 124.2, 122.6, 121.5, 119.4, 118.9, 118.9, 118.3, 111.8, 109.7, 55.0, 53.7, 52.8, 52.4, 40.7, 40.5, 37.5, 28.5, 28.1, 25.8; IR 881 
(ATR).νmax 3272, 3191, 3063, 2103, 1529, 1434, 1340, 1029, 835, 798, 744, 720; HRMS (ESI): m/z calcd for C40H44N8O5 [M + 882 
H]+: 717.3435; found: 717.3501.  883 
 884 
4.3.38. 1H NMR and 13C NMR spectra of N-((S)-6-amino-1-((2-aminoethyl)amino)-1-oxohexan-2-yl)-3'-((S)-2-((S)-2-amino-3-885 
phenylpropanamido)-3-(1H-indol-3-yl)propanamido)-[1,1'-biphenyl]-3-carboxamide (25e) 886 
 887 
The title compound was prepared from compound 24e (90 mg, 0.088 mmol) following the general protocol 4 to afford 25e as a 888 
gummy solid (45 mg, 49%).1H NMR (600 MHz, DMSO-d6): δ 10.91 (s, 1H), 10.36 (s, 1H), 8.97 (d, J = 6.00 Hz, 1H), 8.68 (d, J = 889 
6.00 Hz, 1H), 8.24 (t, J = 6.00 Hz, 1H), 8.16-7.67 (m, 12H), 7.68 (d, J = 6.00 Hz, 1H), 7.62-7.58 (m, 2H), 7.46-7.45 (m, 2H), 7.33 890 
(d, J = 12.00 Hz, 1H), 7.26-7.15 (m, 6H), 7.06 (t, J = 6.00 Hz, 1H), 6.98 (t, J = 6.00 Hz, 1H), 4.81 (q, J = 6.00 Hz, 1H), 4.44-4.41 891 
(m, 1H), 4.09 (t, J = 6.00 Hz, 1H), 3.31-3.30 (m, 2H), 3.27 (dd, J = 6.00, 12.00 Hz, 1H), 3.15-3.09 (m, 2H), 2.97 (dd, J = 12.00, 892 
15.00 Hz, 1H), 2.87 (t, J = 6.00 Hz, 2H), 2.77 (br s, 2H), 1.84-1.81 (m, 1H), 1.76-1.72 (m, 1H), 1.59-1.52 (m, 2H), 1.42-1.32 (m, 893 
2H); 13C NMR (150 MHz, DMSO-d6): δ 172.8, 170.3, 168.5, 166.9, 158.5, 158.3, 140.5, 139.8, 136.6, 135.1, 135.12, 130.0, 894 
129.9, 129.4, 128.8, 127.7, 127.5, 127.2, 126.2, 124.2, 122.6, 121.5, 119.3, 118.9, 118.7, 118.3, 118.8, 109.7, 55.03, 53.8, 53.7, 895 
40.5, 39.5, 39.2, 39.9, 37.4, 36.9, 31.3, 28.4, 27.1, 23.2; IR (ATR).νmax 3274, 3056, 2926, 2119, 1661, 1526, 1431, 1200, 1121, 896 
836, 797, 743, 721; HRMS (ESI): m/z calcd for C41H48N8O4 [M + H]+: 717.3435; found: 717.3501. 897 
 898 
4.3.39. 1H NMR and 13C NMR spectra of N-((S)-6-amino-1-((2-guanidinoethyl)amino)-1-oxohexan-2-yl)-3'-((S)-2-((S)-2-amino-3-899 
phenylpropanamido)-3-(1H-indol-3-yl)propanamido)-[1,1'-biphenyl]-3-carboxamide (25f) 900 
 901 
The title compound was prepared from compound 24f (100 mg, 0.086 mmol) following the general protocol 4 to afford 25f as a 902 
gummy solid (41 mg, 40%).1H NMR (600 MHz, DMSO-d6): δ 10.90 (d, J = 6.00 Hz, 1H), 10.35 (s, 1H), 8.93 (br s, 1H), 8.65 (d, 903 
J = 6.00 Hz, 1H), 8.20-8.13 (m, 4H), 7.96-7.91 (m, 2H), 7.84-7.53 (m, 7H), 7.51-7.43 (m, 2H), 7.37-7.10 (m, 8H), 7.10-7.04 (m, 904 
1H), 7.00-6.97 (m, 1H), 6.54 (br s, 1H), 4.82 (q, J = 6.00 Hz, 1H), 4.47-4.44 (m, 1H), 4.06 (br s, 1H), 3.46-3.39 (m, 2H), 3.27-905 
2.77 (m, 8H), 1.91-1.24 (m, 6H); 13C NMR (150 MHz, DMSO-d6): δ 172.9, 170.3, 166.7, 158.5, 158.3, 157.4, 140.5, 139.7, 136.5, 906 
135.1, 130.0, 129.9, 129.4, 128.9, 127.7, 127.5, 126.3, 124.2, 123.4, 122.63, 122.6, 121.5, 119.4, 118.9, 118.7, 118.4, 118.3 , 907 
116.7, 111.8, 109.7, 54.9, 54.0, 53.7, 40.8, 40.5, 39.2, 38.4, 31.4, 28.5, 27.2, 23.2; IR (ATR).νmax 3265, 3065, 1655, 1537, 1428, 908 
1170, 1128, 1001,787; HRMS (ESI): m/z calcd for C42H50N10O4 [M + H]+: 759.4017; found: 759.4084. 909 
 910 
4.3.40.1H NMR and 13C NMR spectra of 3'-((S)-2-((S)-2-amino-3-phenylpropanamido)-3-(1H-indol-3-yl)propanamido)-N-((S)-5-911 








The title compound was prepared from compound 24g (48 mg, 0.036 mmol) following the general protocol 4 to afford 25g as a 914 
gummy solid (20 mg, 40%).1H NMR (600 MHz, DMSO-d6): δ 10.84 (s, 1H), 10.27 (s, 1H), 8.84 (s, 1H), 8.62 (d, J = 6.00 Hz, 915 
1H), 8.16-8.11 (m, 2H), 7.94 (d, J = 6.00 Hz, 1H), 7.76 (d, J = 12.00 Hz, 1H), 7.67 (d, J = 12.00 Hz, 1H), 7.62-7.56 (m, 3H), 7.46 916 
(d, J = 6.00 Hz, 2H), 7.34 (d, J = 12.00 Hz, 1H), 7.28-7.14 (m, 8H), 7.08-7.06 (m, 2H), 7.01-6.97 (m, 1H), 4.82 (q, J = 6.00 Hz, 917 
1H), 4.51-4.46 (m, 1H), 4.07 (br s, 1H), 3.25-3.19 (m, 6H), 3.15-3.12 (m, 3H), 2.96-2.94 (m, 1H), 1.89-1.84 (m, 1H), 1.76-1.72 918 
(m, 1H), 1.60-1.50 (m, 2H); 13C NMR (150 MHz, DMSO-d6): δ 172.6, 170.3, 166.8, 158.6, 158.4, 158.2, 157.5, 157.2, 140.6, 919 
140.5, 139.8, 136.6, 135.1, 130.0, 130.0, 129.8, 129.4, 128.8, 128.8,  127.7, 127.4, 127.2, 126.2, 124.1, 122.6, 121.4, 119.4, 118.9, 920 
118.7, 118.4, 116.8, 111.8, 109.8, 55.0, 53.5, 40.98, 40.9, 40.6, 38.4, 29.1, 28.4, 25.8; IR (ATR).νmax 3279, 3186, 3086, 1646, 921 
1529, 1431, 1175, 1125, 798, 743; HRMS (ESI): m/z calcd for C42H50N12O4 [M + H]+: 787.4078; found: 787.4152. 922 
 923 
4.3.41. 1H NMR and 13C NMR spectra of 3'-nitro-[1,1'-biphenyl]-3-carboxylic acid (26) 924 
 925 
To the solution of 9 (1.2 g, 3.88 mmol) in THF (10.0 mL) and MeOH (10.0 mL), was added a 1N NaOH(aq) (7.77 mL, 7.77 mmol) 926 
and stirred at room temperature for 16 h. Ethyl acetate was added and the layers were separated. The aqueous layer was then 927 
acidified with 1N HCl and then extracted with CH2Cl2 (2 X 100 mL) and then the solvent was removed under reduced pressure to 928 
yield 26 (0.84 g, 90%) as a pale-yellow solid; m.p.: 209.4–210.6 °C; 1H NMR (400 MHz, DMSO-d6): δ 13.19 (br s, 1H), 8.44 (s, 929 
1H), 8.25 (br s, 2H), 8.18 (d, J = 7.60 Hz, 1H), 8.02 (t, J = 8.00 Hz, 1H), 7.78 (t, J = 8.00 Hz, 1H); 13C NMR (100 MHz, DMSO-930 
d6): δ 167.5, 148.9, 141.3, 138.6, 133.9, 132.2, 131.9, 131.1, 130.1, 129.8, 128.1, 123.1, 121.8; IR (ATR).νmax 2965, 2840, 2541, 931 
2099, 1681, 1590, 1514, 1421, 1189, 1095, 928, 853; HRMS (ESI): m/z calcd for C13H9NO4Na [M + Na]+: 266.0429; found: 932 
266.0424. 933 
 934 
4.3.42. 1H NMR and 13C NMR spectra of N-(2-(2,3-dibocguanidino)ethyl)-3'-nitro-[1,1'-biphenyl]-3-carboxamide (27) 935 
 936 
The title compound 27 was prepared from compound 18b (0.621 g, 2.00 mmol) and 33 (0.5 g, 2.00 mmol) according to the 937 
protocol 2. Off-white solid (0.47 g, 45%); m.p.: 117.6–118.9 °C; 1H NMR (400 MHz, CDCl3): δ 11.51 (br s, 1H), 8.83-8.82 (m, 938 
1H), 8.26-8.16 (m, 3H), 8.00-7.97 (m, 1H), 7.84-7.82 (m, 1H), 7.66-7.63 (m, 1H), 7.56 (t, J = 8.00 Hz, 1H), 3.80-3.77 (m, 2H), 939 
3.71-3.67 (m, 2H), 1.51 (s, 9H), 1.49 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 167.1, 162.7, 157.9, 153.0, 148.8, 142.0, 139.1, 940 
135.4, 133.2, 129.9, 129.8, 129.1, 126.9, 126.3, 122.4, 122.0, 83.8, 79.9, 79.7, 42.5, 39.7, 28.3, 28.2, 28.0; IR (ATR).νmax 3196, 941 
2985, 2930, 1784, 1719, 1532, 1473, 1268, 1139, 869; HRMS (ESI): m/z calcd for C41H51N5O8 [M + Na]+: 550.2278; found: 942 
550.2273. 943 
 944 
4.3.43. 1H NMR and 13C NMR spectra of 3'-amino-N-(2-guanidinoethyl)-[1,1'-biphenyl]-3-carboxamide (28) 945 
 946 
The title compound 28 was prepared from 27 (0.25 g, 0.47 mmol) according to the protocol 4. Pale brown solid (139 mg, 90% 947 
yield); m.p.: 183.8–184.5 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.93 (t, J = 5.20 Hz, 1H), 8.54 (t, J = 2.00 Hz, 1H), 8.28-8.25 (m, 948 
3H), 7.98 (t, J = 7.60 Hz, 2H), 7.83-7.75 (m, 2H), 7.65 (t, J = 8.00 Hz, 1H), 7.26 (br s, 3H), 3.48-3.43 (m, 2H), 3.39-3.35 (m, 2H); 949 
13C NMR (100 MHz, DMSO-d6): δ 166.8, 157.5, 148.9, 141.5, 138.3, 135.5, 133.9, 131.1, 130.3, 129.8, 128.0, 126.1, 123.0, 950 
121.7, 40.7, 39.1; IR (ATR).νmax 3280, 3155, 2341, 2112, 1638, 1522, 1457, 1344, 1299, 1192, 1114, 996, 864, 798, 675, 730; 951 
HRMS (ESI): m/z calcd for  C16H17N5O3 [M + H]+: 327.1331; found: 328.1401. 952 
 953 
4.3.44. 1H NMR and 13C NMR spectra of 3'-amino-N-(2-guanidinoethyl)-[1,1'-biphenyl]-3-carboxamide (29) 954 
 955 
To a stirred solution of 28 (0.1 g, 0.305 mmol) in anhydrous THF (100 mL) under nitrogen atmosphere 10% palladium on 956 
activated charcoal (0.15 g) was added. The reaction was evacuated and placed under a hydrogen atmosphere and stirred overnight. 957 
The reaction mixture was filtered through celite, and the solvent was removed under reduced pressure to yield the desired product 958 
29 as a brown solid (39 mg, 40% yield); m.p.: 233.0–233.6°C; 1H NMR (400 MHz, DMSO-d6): δ 8.76 (t, J = 5.20 Hz, 1H), 8.07 959 
(br s, 1H), 7.83 (d, J = 7.60 Hz, 1H), 7.72 (d, J = 8.00 Hz, 1H), 7.66 (t, J = 5.60 Hz, 1H), 7.54 (t, J = 8.00 Hz, 1H), 7.14 (t, J = 960 
7.60 Hz, 1H), 6.90-6.84 (m, 2H), 6.62-6.59 (m, 1H), 5.28 (br s, 2H), 3.44-3.37 (m, 4H); 13C NMR (100 MHz, DMSO-d6): δ 167.2, 961 
157.5, 149.5, 141.6, 140.6, 135.0, 129.9, 129.7, 129.3, 126.4, 125.7, 115.0, 114.0, 112.7, 40.8, 39.0;  IR (ATR).νmax 3262, 3144, 962 
2849, 2587, 2342, 1621, 1541, 1471, 1309, 1182, 1129, 807; HRMS (ESI): m/z calcd for C16H19N5O [M + H]+: 298.1590; found: 963 
298.1660. 964 
 965 
4.3.45. 1H NMR and 13C NMR spectra of Methyl L-tryptophanate (31) 966 
 967 
The title compound 31 was prepared by adding thionyl chloride (0.79 mL, 9.80 mmol) dropwise to L-Tryptophan (1.0 g, 4.90 968 
mmol) in methanol (20.0 mL) at 0° C and then stirred at room temperature for 16 h. The solvents were removed and reduced 969 
pressure and the residue was diluted with ethylacetate (100.0 mL) and washed with saturated NaHCO3(40 mL), saturated brine (40 970 
mL), then dried (Na2SO4) and concentrated under reduced pressure to afford a white solid (1.00 g, 94%); m.p.: 89.4–89.9 °C;  1H 971 
NMR (400 MHz, DMSO-d6): δ 10.87 (s, 1H), 7.48 (d, J = 8.00 Hz, 1H), 7.33 (d, J = 8.00 Hz, 1H), 7.12 (br s, 1H), 7.05 (t, J = 972 
8.00 Hz, 1H), 6.97 (t, J = 8.00 Hz, 1H), 3.63 (t, J = 8.00 Hz, 1H), 3.55 (s, 1H), 3.05-2.91 (m, 2H); 13C NMR (100 MHz, DMSO-973 
d6): δ 176.1, 136.5, 127.8, 124.1, 121.3, 118.8, 118.7, 111.8, 110.3, 55.6, 51.8, 40.6, 31.1; IR (ATR).νmax 3356, 3292, 3096, 974 
3051, 2916, 2871, 2338, 2095, 1727, 1567, 1448, 1351, 1290, 1222, 1104, 1012, 945, 890, 805, 737; HRMS (ESI): m/z calcd for 975 
C12H14N2O2 [M + H]+: 219.1055; found: 219.1125. 976 
 977 








The title compound was prepared via protocol 1, using N-(tert-Butoxycarbonyl)-L-phenylalanine (1.21 g, 4.6 mmol) and 31 (1.00 980 
g, 4.6 mmol) to afford the coupled product 32 as an off-white solid (1.40 g, 65%); m.p.: 135.3–135.7 °C; 1H NMR (400 MHz, 981 
DMSO-d6): δ  10.89 (s, 1H), 8.29 (d, J = 8.00 Hz, 1H), 7.49 (d, J = 8.00 Hz, 1H), 7.34 (d, J = 8.00 Hz, 1H), 7.23-7.18 (m, 6H), 982 
7.07 (t, J = 8.00 Hz, 1H), 6.99 (t, J = 8.00 Hz, 1H), 6.87 (d, J = 12.00 Hz, 1H), 4.55 (q, J = 8.00 Hz, 1H), 4.23-4.18 (m, 1H), 3.55 983 
(s, 3H), 3.20-3.07 (m, 2H), 2.95-2.90 (m, 1H), 2.72-2.66 (m, 1H), 1.28 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 172.6, 172.2, 984 
155.6, 138.5, 136.5, 129.6, 128.4, 127.5, 126.6, 124.2, 121.4, 118.9, 118.4, 111.8, 109.6, 78.5, 56.0, 53.5, 52.2, 37.8, 28.5, 28.2, 985 
27.5; IR (ATR).νmax 3295, 3001, 2952, 1694, 1648, 1525, 1433, 1288, 1164, 1112, 922, 846; HRMS (ESI): m/z calcd for 986 
C26H31N3O5 [M + H]+: 465.23; found: 337.14340 987 
 988 
4.3.47. 1H NMR and 13C NMR spectra of (tert-butoxycarbonyl)-L-phenylalanyl-L-tryptophan (33) 989 
 990 
To a solution of 31 (1.4 g, 3.00 mmol) in THF (10.0 mL) and MeOH (10.0 mL), was added a 1N NaOH(aq) (6.0 mL, 6.00 mmol) 991 
and stirred at room temperature for 16 h. Ethyl acetate was added and the layers were separated. The aqueous layer was then 992 
acidified with 1N HCl and then extracted with CH2Cl2 (2 X 100 mL) and then the solvent was removed under reduced pressure to 993 
yield 33 (1.23 g, 91%) as an off-white solid; m.p.: 133.2–134.0 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.89 (s, 1H), 8.08 (d, J = 994 
8.00 Hz, 1H), 7.54 (d, J = 8.00 Hz, 1H), 7.33 (d, J = 8.00 Hz, 1H), 7.24-7.17 (m, 6H), 7.08-7.04 (m, 1H), 7.00-6.96 (m, 1H), 6.87 995 
(d, J = -8.00 Hz, 1H), 4.51 (q, J = 8.00 Hz, 1H), 4.21-4.15 (m, 1H), 3.25-3.17 (m, 1H), 3.11-3.06 (m, 1H), 2.96-2.92 (m, 1H), 996 
2.71-2.65 (m, 1H), 1.28 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 173.6, 172.1, 155.6, 138.5, 136.5, 129.6, 128.4, 127.7, 126.5, 997 
124.1, 121.3, 118.8, 118.6, 111.8, 110.3, 110.0, 78.5, 56.1, 53.3, 37.9, 31.4, 28.5, 27.5, 22.5, 14.4; IR (ATR).νmax 3310, 3046, 998 
2926, 1650, 1509, 1436, 1364, 1247, 1158, 1011, 848; HRMS (ESI): m/z calcd for C25H29N3O5Na[M + H]+: 474.2005; found: 999 
474.1998. 1000 
 1001 
4.3.48. 1H NMR and 13C NMR spectra of tert-butyl ((S)-1-(((S)-1-((2-(2,3-dibocguanidino)ethyl)amino)-3-(1H-indol-3-yl)-1-1002 
oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (34) 1003 
 1004 
The title compound 34 was prepared from compound 18b (0.333 g, 1.1 mmol) and 33 (0.5 g, 1.1 mmol) according to the protocol 1005 
2. Off-white solid (0.36 g, 45%); m.p.: 180.6–181.2 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.47 (br s, 1H), 10.80 (d, J = 4.00 Hz, 1006 
1H), 8.37 (t, J = 4.00 Hz, 1H), 8.13 (t, J = 4.00 Hz, 1H), 7.91 (d, J = 8.00 Hz, 1H), 7.57 (d, J = 8.00 Hz, 1H), 7.30 (d, J = 8.00 Hz, 1007 
1H), 7.20-7.06 (m, 6H), 7.07-7.02 (m, 1H), 6.98-6.94 (m, 1H), 6.88 (d, J = 8.00 Hz, 1H), 4.48 (q, J = 4.00 Hz, 1H), 4.15-4.09 (m, 1008 
1H), 3.27-2.95 (m, 6H), 2.90-2.85 (m, 1H), 2.69-2.63 (m, 1H), 1.44 (s, 9H), 1.38 (s, 9H), 1.28 (s, 9H); 13C NMR (100 MHz, 1009 
DMSO-d6): δ 172.0, 171.6, 163.5, 156.0, 155.6, 152.3, 138.5, 136.5, 129.6, 128.4, 127.8, 126.6, 124.0, 121.3, 118.9, 118.6, 111.7, 1010 
110.3,83.3, 78.7, 78.6, 56.4, 53.8, 38.5, 37.9, 37.8, 28.6, 28.5, 28.4, 28.1; IR (ATR).νmax 2974, 1637, 1523, 1363, 1248, 1132, 1011 
1021; HRMS (ESI): m/z calcd for C38H53N7O8 [M + H]+: 736.3956; found: 736.4023. 1012 
 1013 
4.3.49. 1H NMR and 13C NMR spectra of (S)-2-amino-N-((S)-1-((2-guanidinoethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-3-1014 
phenylpropanamide (35 TFA Salt) 1015 
 1016 
The title compound was prepared via protocol 4, using 34 (0.150 g, 0.203 mmol) to yield the desired product 35 as a brown 1017 
gummy solid (40 mg, 47%). 1H NMR (400 MHz, DMSO-d6): δ 10.87 (br s, 1H), 8.81 (d, J = 8.00 Hz, 1H), 8.30 (t, J = 4.00 Hz, 1018 
1H), 8.06 (br s, 3H), 7.64-7.62 (m, 2H), 7.34-7.24 (m, 9H), 7.16 (d, J = 4.00 Hz, 1H), 7.08-7.04 (m, 1H), 7.00-6.96 (m, 1H), 4.58-1019 
4.52 (m, 1H), 4.03 (br s, 1H), 3.26-2.88 (m, 8H); 13C NMR (100 MHz, DMSO-d6): δ 172.0, 168.3, 157.5, 136.6, 135.2, 130.0, 1020 
129.0, 127.64, 127.6, 124.3, 121.4, 118.9, 118.7, 111.8, 110.0, 54.2, 53.6, 38.5, 37.5, 28.6; IR (ATR).νmax 3060, 2919, 1670,  1021 
1542, 1421, 1199, 1128, 1002, 825; HRMS (ESI): m/z calcd for C23H29N7O2 [M + H]+: 436.2383; found: 436.2451. 1022 
 1023 
4.4 Antibacterial activity 1024 
 1025 
The antimicrobial activity of compounds was evaluated through the broth micro dilution assay using the procedure described by 1026 
CLSI.[64] Briefly, Staphylococcus aureus [SA38] were grown to mid-log phase in Muller-Hinton broth (MHB) with shaking at 1027 
120 rpm and incubated at 37 °C for 18-24 h. Following incubation, bacteria were washed three times using PBS pH 7.4 with 1028 
centrifugation at 3500 g for 10 min after each wash. After washing, bacteria were diluted with fresh MHB. The turbidity of the 1029 
bacterial suspensions were adjusted so that OD600nm was 0.1, which gave 1×108 cfu/ml, and then further diluted to achieve 1-2×105 1030 
cfu/ml as a final bacterial concentration. Each compound was added at concentrations ranging from 250-3.9 µM through serial 1031 
two-fold dilution. Wells in microtitre plates were loaded with 100 µl of inoculum containing 1-2×105 cfu/ml bacteria. Wells 1032 
containing only bacteria and without any compound were used as a negative controls (i.e. no inhibition of growth). Wells without 1033 
bacteria but containing compound acted as another control. The microtitre plate was wrapped with paraffin to prevent evaporation 1034 
and incubated with shaking at 120 rpm and 37 °C for 18-24 h. After incubation, spectrophotometric reading of the wells was taken 1035 
at 600nm. The minimal inhibitory concentration (MIC) was defined as the lowest concentration of the biphenyl compounds that 1036 
causes 100% inhibition of microbial growth. The same procedure was followed for the two Gram-negative bacteria, Pseudomonas 1037 
aeruginosa [PA01], and Escherichia coli [K12]. Each experiment was performed in triplicate and was repeated in three 1038 
independent experiments. The MICs of the compounds were compared to published MIC [15, 52, 53] of MSI-78. The method for 1039 
determining the MIC of MSI-78 [52, 53] , that recommended by the CLSI (formerly named the National Committee for Clinical 1040 
Laboratory Standards (NCCLS)) was exactly the same as described herein for the current compounds. 1041 
 1042 








Normal human lung fibroblasts MRC-5 were cultured in minimal essential medium (MEM, Invitrogen) supplemented with 10% 1045 
foetal calf serum (FCS), 1% L-glutamine–penicillin–streptomycin, 2% sodium bicarbonate, 1% non-essential amino acids 1046 
(NEAA) and 1% sodium pyruvate. The cell line was maintained at 37 °C in 5% CO2 as an adherent monolayer and was passaged 1047 
upon reaching confluence by standard cell culture techniques. MRC-5 cells were seeded at 2 × 104 cells per well in 96-well plates 1048 
to ensure full confluence (quiescence). Cells were treated 24 h after seeding with 0.1 to 1000 μM of compounds. After 72 h drug 1049 
incubation, the treated media was replaced with fresh media containing 10% Alamar blue and the cells were incubated for another 1050 
6 h. The metabolic activity was detected by spectrophotometric analysis by assessing the absorbance of Alamar blue as previously 1051 
described by Pasquier et al. [65] Cell proliferation was determined and expressed as a percentage of untreated control cells. The 1052 
determination of IC50 values was performed using GraphPad Prism 6 (San Diego, CA, USA).]. Each experiment was performed in 1053 
triplicate and was repeated in three independent experiments. 1054 
 1055 
4.6 Tethered bilayer lipid membranes 1056 
 1057 
The ability of the biphenyl derivatives to interact with lipid bilayers was tested using tethered bilayer lipid membranes (tBLMs) in 1058 
association with AC electrical impedance spectroscopy techniques [55, 56]. Lipid bilayers were anchored to a gold substrate 1059 
which were created using the solvent exchange technique described previously [56, 57]. In short, tethered benzyl-disulfide (tetra-1060 
ethyleneglycol) n=2 C20-phytanyl tethers: benzyl-disulfide-tetra-ethyleneglycol-OH spacers were pre-prepared in the ratio of 1:10 1061 
and were coated onto a gold patterned polycarbonate slide containing a large gold return electrode (SDx Tethered Membranes Pty 1062 
Ltd, Australia). Attached to this slide was a specialised cartridge chamber which allows for easy addition of reagent between 1063 
tethering and reference electrodes. A 3 mM solution of a standard mobile lipid phase [70% zwitterionic C20 Diphytanyl-Glycero-1064 
Phosphatidylcholine lipid: 30% C20 Diphytanyl-diglyceride-OH ether] was added to the tethering chemistries. All lipids were 1065 
dissolved in 100% ethanol. Lipids were left for 2 minutes to associate with the tethering chemistries before being washed with 3 x 1066 
200 ml phosphate buffered saline (PBS). The membranes formed from these lipids are designated as the “zwitterionic 1067 
membranes”. Alternatively, negatively charged membranes, that resemble those present in many bacterial species, were produced 1068 
using the same mobile lipid phase which was instead supplemented with 30% palmitoyl-oleoyl-phosphatidylglycerol (POPG) 1069 
(Avanti Lipids, USA). The presence of a lipid bilayer was verified using AC electrical impedance spectrometry. These measures 1070 
were done using a TethaPod™ operated with TethaQuick™ software (SDx Tethered Membranes Pty Ltd, Australia). The signal 1071 
employed was 50 mV peak-to-peak AC excitation at 0.1–2000 Hz with four steps per decade. Impedance data were fitted to a 1072 
constant phase element (CPE) in series with a resistor/capacitor. The CPE represents the capacitance of the gold electrode 1073 
interface, whist the resistor and capacitor represent the resistance and capacitance of the tethered membrane respectively. Fitting 1074 
was done using a proprietary adaptation of a Lev Mar fitting routine as described previously [56]. All tethered membrane assays 1075 
were performed in triplicate. Individual results shown are of typical responses to the antimicrobial compounds. 1076 
 1077 
4.7 Cytoplasmic membrane permeability assay 1078 
 1079 
The method was adopted from Wu et al. [66] with slight modification. Bacterial cytoplasmic membrane permeability was 1080 
determined using membrane potential sensitive dye diSC3-5 (3,3'-dipropylthiadicarbocyanine iodide) which penetrates inside 1081 
bacterial cells depending on the membrane potential gradient of the cytoplasmic membrane. Staphylococcus aureus [SA38] and 1082 
Escherichia coli [K12] were grown in MHB to mid-log phase by incubating with shaking at 37 °C for 18-24 h. Following 1083 
incubation bacteria were washed with 5 mM HEPES containing 20 mM glucose pH (7.2) and resuspended in the same buffer to an 1084 
OD600 0.05-0.06 which gave 1× 107 CFU/ml. diSC3-5 was added at 4 µM to the bacterial suspension. The suspensions were 1085 
incubated at room temperature for 1 h in the dark for maximum dye take-up by bacterial cell. Then, 100 mM KCl was added to 1086 
balance the K+ outside and inside the bacterial cell to prevent further uptake or outflow of the dye. For Gram-negative bacteria, 1087 
0.5 mM EDTA was used to remove the stabilizing divalent cations from the lipopolysaccharide (LPS) layer which help in dye 1088 
penetration without affecting bacterial growth. 100 µl of bacterial suspension was added in a 96-well microtiter plate with equal 1089 
volume of antimicrobial compounds. Dimethyl sulfoxide (DMSO) was used as a positive control to achieve maximum 1090 
fluorescence while bacterial suspension containing only dye and HEPES buffer set as blank to subtract the background. 1091 
Fluorescence was measured with a luminescence spectrophotometer at 3 min intervals at an excitation wavelength of 622 nm and 1092 
an emission wavelength of 670 nm. The experiment was performed in triplicate.  1093 
 1094 
4.8 Biofilm inhibition assay 1095 
 1096 
Bacterial cultures (S. aureus and E. coli) were grown in LB10 media overnight at 37 °C with shaking at 150 rpm. Cultures were 1097 
diluted (1:20) in LB medium and 200 μl aliquots were dispensed to flat bottom 96-well plate wells (Sarstedt Australia). Cultures 1098 
were supplemented with varying concentrations of synthetic compounds dissolved in DMSO. The cultures were grown in 96-well 1099 
plate wells overnight along with synthetic compounds. Control cultures were supplemented with an equal amount of DMSO. 1100 
Plates were sealed with self-adhesive microplate sealers (TopSeal-A, PerkinElmer) to allow air diffusion and to prevent 1101 
condensation. Cultures were incubated overnight at 37 °C with shaking at 150 rpm. Biofilms adhered on polystyrene substratum 1102 
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